<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002307" GROUP_ID="AIRWAYS" ID="143300030315162827" MERGED_FROM="" MODIFIED="2009-04-27 16:06:53 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Technical editing by CJC 28_1_03&lt;/p&gt;&lt;p&gt;Croris: Thanks for the rapid turn around and comments.&lt;br&gt;Authors Contribution: fine&lt;/p&gt;&lt;p&gt;References: Missing for Bund pdr and Rasmussen 1979. Please add. DONE[thanks]&lt;/p&gt;&lt;p&gt;Table of included studies: Good to see the details of when and how sd was estimated.&lt;/p&gt;&lt;p&gt;Metaview Labels: Fine but 2~6 was reversed so graph labels changed. Also 2~8 relabelled as B2 to be the same as the other outcomes. Is there any double counting in the studies in 2~7? Are all the Bund patients different?&lt;br&gt;Chris: I CHANGED ALL TO SABA TO AGREE WITH TEXT&lt;br&gt;Carol: OK; thanks.&lt;/p&gt;&lt;p&gt;Synopsis: No change.&lt;/p&gt;&lt;p&gt;Abstract: &amp;quot;Compared to SABA agents, MCS were less effective at improving pulmonary functions (maximum % decrease WMD=6.8%; 95%CI: 4.5 to 9.2), providing complete protection (85% vs 66%; OR=0.3; 95% CI: 0.2 to 0.5) and producing clinical protection (77% vs 55%; OR=0.4; 95% CI: 0.2 to 0.8). There were no subgroup differences based on age, severity, drug, delivery, or study quality.&amp;quot; I have reversed the order of treatments to make the Odds Ratios correct. &lt;br&gt;Carol: OK&lt;/p&gt;&lt;p&gt;Methods - Subgroup analysis moved into here. Any reason why you used a Random model throughout?&lt;br&gt;Carol: Always use RE to provide a more conservative estimate; moreover, there is no differene between RE and FE in most of the analyses.. &lt;/p&gt;&lt;p&gt;Results_ &amp;quot;MCS compared to SABA agent:&lt;br&gt;When MCS were compared to SABA, both attenuated the EIB response; SABAs afforded a statistically significant advantage over MCS. From 12 trials, the mean max % fall PFT favoured SABA (WMD = 6.8%; 95% CI: 4.5 to 9.2%). The pooled result from the 5 studies that reported a TBI also favoured SABA (WMD = 14.7%; 95% CI: 9.1 to 20.3%). The result was not significantly different in the sub-group comparison by age (children WMD = 7.3%; 95% CI: 3.9 to 10.7% vs adult WMD 6.4%; 95% CI:2.7 to 10.1). &lt;/p&gt;&lt;p&gt;SABA compared to combination SABA + SCG: &lt;br&gt;No statistically or clinically significant advantage was identified when SABA alone was compared to a combination of SABA + MCS; however, in all but one study the point estimate favoured the combination. In 9 trials, the mean max % fall PFT was similar (WMD = 0.5%; 95% CI: -0.8 to 1.8%). The result was not significantly different in the sub-group comparison by age (children WMD = 0.8%; 95% CI: -0.7 to 2.3% vs adult WMD = -0.7%; 95% CI: -3.5 to 2.1)&amp;quot;&lt;/p&gt;&lt;p&gt; I have changed the CIs here to match metaview in the first para and WMD is -0.7 in the second.&lt;/p&gt;&lt;p&gt;Carol: I edited these paragraphs a little&lt;/p&gt;&lt;p&gt;Discussion : Fine&lt;br&gt;Carol: thnaks.&lt;/p&gt;&lt;p&gt;Contentious issues: I assume that baselines were taken BEFORE the treatment was given (as SABA increased the readings more before the exercise started). &lt;br&gt;Carol: YES&lt;/p&gt;&lt;p&gt;Next action : Back to Carol to enter the two missing references DONE and clarify that the Top to Bottom patients in all the trials are different from each other. &lt;br&gt;Carol: YES THEY ARE - I NOTED TAHT THEY WERE INDEPENDENT PARTICIPANTS. [thanks]&lt;/p&gt;&lt;p&gt;I would also add a postscript about RevMan not being the best package for cross-overs, but if anything this is likely to lead to results that are over cautious. &lt;br&gt;arol: I ADDED TO THE DISCUSSION AT THE END. SEE WHAT YOU THINK [fine]&lt;/p&gt;&lt;p&gt; In a future update an inverse variance method will be available to pool the data if paired t-tests are reported in the papers. Do the confidence intervals in RevMan bear any resemblance to those reported in the trials (if so this can be mentioned as a validity check!)&lt;br&gt;Carol: do you really think this is necessary BEFORE the event? [it can wait until then].&lt;/p&gt;&lt;p&gt;Regards,&lt;/p&gt;&lt;p&gt;Carol&lt;/p&gt;&lt;p&gt;25/2/03&lt;br&gt;Thanks for making the changes above. I am interested in the issue of clinical and statistically significant differences as mentioned in your results:&lt;br&gt;&amp;quot;MCS compared to SABA agent:&lt;br&gt;When MCS were compared to SABA, both attenuated the EIB response; SABAs afforded a statistically but not clinically significant advantage over MCS. &amp;quot;&lt;br&gt;The fact is that the mean difference between treatments is less than the 12% specified, but the OR suggests to me a sizeable difference in the number of patients achieving protection. To me this means that the difference is CLINICALLY important; some patients will gain adequate protection from MCS but more from SABA. With your permission I have altered this to a significant advantage....... and added a sentence about the wmd and OR at the end of the paragraph.&lt;br&gt;I WOULD LIKE TO USE THIS AS AN EXAMPLE OF THE DIFFICULTIES IN USING A MEAN DIFFERENCE THAT DOES NOT REACH CLINICAL SIGNIFICANCE IN THE MEETING IN CANADA IN THE SUMMER WITH YOUR PERMISSION?&lt;/p&gt;&lt;p&gt;I will return this to Toby to add the Senn reference and then it is ready for the Library.&lt;br&gt;Cheers,&lt;br&gt;Chris.&lt;br&gt;---------------------------------------------------------------------------------------------------------------------------------------------------------------------&lt;br&gt;23-May-03&lt;br&gt;Peer review comments from Peer reviewer&lt;br&gt; Abstract&lt;br&gt;Adequate presentation of key results ?&lt;br&gt;In general yes. I have some difficulties with the wording: eg &amp;#8220;&amp;#8230;compared to AC, MCS agents were statistically but not clinically significant for improving pulmonary function (max % decrease WMD = 5.88%&amp;#8230;)&amp;#8221; [OMITTED THIS COMMENT] &lt;br&gt;What I think this actually means is the MCS were more effective in preventing a deterioration in either FEV1 or PEF after exercise. Interpreting the WMD between treatments is difficult without some indication of how effective each agent was (eg MCS reduced the fall by 12% compared to 6% for ACs would be interpreted quite differently from MCS reducing the fall by 88% compared to 82% for ACs). ADDED THIS INFORMATION THROUGHOUT&lt;br&gt;Also the distinction between statistically significant and clinically significant is important, but is difficult to justify from this data. We are told that a 12% improvement if pulmonary function is required for clinical significance. This is obviously an arbitrary figure, and I&amp;#8217;m not sure that it was generated for comparing 2 treatments. In this context, when EIB is defined as a fall in FEV1/PEF of &amp;gt;10%, requiring a 12% improvement in pulmonary function is unreasonable. [OMITTED THIS COMMENT] &lt;/p&gt;&lt;p&gt;Clinical context&lt;br&gt;Definition of disease and patient population ?&lt;br&gt;The definition of EIB and the population is reasonable. There is insufficient information on the background of the participant. [INFORMATION REQUIRED NOT REPORTED. INSERTED STATEMENTS TO THAT EFFECT]&lt;br&gt;This particularly concerns the use of inhaled/oral steroids and inhalked beta-agonists. The response to SABA might be (will be) very attenuated in a patient who uses regular beta-agonists. It is at least plausible that inhaled steroids would alter the response to SABA or MCS. PERFORMED A POST HOC COMPARISON BUT COULD ONLY DO THOSE WHO EXCLUDED ALL STEROID USERS. oTHERS WERE MIXED OR NOT REPORTED.&lt;/p&gt;&lt;p&gt; Results of analysis (if applicable)&lt;br&gt;Clarity ?&lt;br&gt;Partly because of the nature of the subject, it is difficult to put the WMDs in context (see comment on abstract above). I am assuming that a 6% difference between drugs implies a 6% difference in the absolute fall in FEV1, not a 6% difference between the falls, or a 6% difference in the extent to which the falls were attenuated. This would be clearer if the mean falls for each drug were described.&lt;br&gt;ADDED MEAN FALLS ALONG WITH WMD&lt;br&gt; Discussion&lt;br&gt;Reflects the results of the analysis ?&lt;br&gt;In general yes. However, the TBI trials seemed to show a significant advantage of combined SCG and SABA over SABA alone in the results. This is not mentioned in the discussion, and it is suggested that there is no benefit. I DO NOT BELIEVE THIS IS THE CASE. SEE COMPARISON 3, OUTCOME2&lt;/p&gt;&lt;p&gt;Sets the results into the appropriate clinical context ?&lt;br&gt;No. One of the most important clinical problems with regard to EIB is whether the tolerance develops with sustained use of the drugs.ISSUE NOT ADDRESSED IN STUDIES. ADDED TO FUTURE RESEARCH&lt;br&gt; It has been demonstrated that significant loss of bronchoprotection to EIB develops soon after starting long-acting beta-agonists. The same is likely to be true in patients who regularly use SABAs. The question as to which drug is most effective in this context is much more important clinically than which drug, given as a one-off, is more effective. Few patients with significant EIB are likely to use only occasional doses of a SABA and no other drugs. The important issue of use of inhaled steroids should also be discussed. &lt;/p&gt;&lt;p&gt; Recommendations for further research ?&lt;/p&gt;&lt;p&gt;Needs to address the tolerance issue. ADDED ALONG WITH ABOVE&lt;/p&gt;&lt;p&gt;&lt;br&gt;Additional comments&lt;br&gt;Please feel free to offer any additional comments you feel are relevant to the overall quality of the review.&lt;/p&gt;&lt;p&gt;The review seems to have been well done. What is missing is consideration of the questions facing clinicians. Should patients with significant EIB be treated with inhaled steroids (almost certainly yes)? If they also use a long-acting beta-agonist, will a SABA be of much use in preventing residual EIB (almost certainly not)? THIS CANNOT BE ADDRESSED WITH EXISTING DATA&lt;/p&gt;&lt;p&gt;The definition of &amp;#8220;complete protection&amp;#8221; being a fall in FEV1/PEF of &amp;lt;15% does not make sense given that &amp;#8220;significant EIB&amp;#8221; is defined as a fall in FEV1/PEF of 10% or greater. 10% IS A POINT OF SUSPICION FOR EIB AND DOES NOT INDICATE 'SIGNIFICANT' EIB. 15% IS THE LOWEST REQUIREMENT IN ALL STUDIES.&lt;br&gt;There are too many abbreviations/acronyms &amp;#8211; I counted 9 in the abstract alone. There are many more in the rest of the text. I appreciate the need for some abbreviation, but this is getting close to unreadable. CHANGED SOME MORE&lt;br&gt;------------------------------------------------------------------------------------------&lt;br&gt;23 May 2003&lt;br&gt;Dear Carol and Brian,&lt;br&gt;Please see the peer reviewers comments above. I have stripped the abbreviations out of the abstract and shortened the synopsis. I think he has some valid points regarding definitions and co-interventions (especially inhaled steroids and habituation to beta-agonists). I would be grateful if you could look through these and perhaps make a few amendments accordingly. Feel free to use the highlighter facility in RevMan 4.2 to show changes!&lt;br&gt;Good to see you both in Edmonton.&lt;br&gt;Cheers,&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;Old title: +Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction&lt;br&gt;____________________________________________________&lt;br&gt;Thanks for making the above changes Carol! A lot of hard work but I think the review overall is better for making the changes.&lt;br&gt;THIS IS NOW READY FOR PUBLICATION. 6_6_3&lt;/p&gt;&lt;p&gt;Refs &amp;amp; SS section checked 16/08/05 Liz&lt;/p&gt;" NOTES_MODIFIED="2009-04-27 15:05:07 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="MCS-AST" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2009-04-27 16:06:53 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction</TITLE>
<CONTACT MODIFIED="2009-04-27 16:06:53 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="5452" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Carol</FIRST_NAME><LAST_NAME>Spooner</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>cspooner@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Emergency Medicine</DEPARTMENT><ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION><ADDRESS_1>8440 - 112 ST</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407-7576</PHONE_1><FAX_1>+1 780 407-3314</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-04-27 16:06:53 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="5452" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Carol</FIRST_NAME><LAST_NAME>Spooner</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>cspooner@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Emergency Medicine</DEPARTMENT><ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION><ADDRESS_1>8440 - 112 ST</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407-7576</PHONE_1><FAX_1>+1 780 407-3314</FAX_1></ADDRESS></PERSON><PERSON ID="12503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>G Richard</FIRST_NAME><LAST_NAME>Spooner</LAST_NAME><SUFFIX>MD, CCFP, FCFP</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>rick.spooner@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>Faculty of Medicine and Dentistry, University of Alberta</ORGANISATION><ADDRESS_1>12-105 Clinical Sciences Building</ADDRESS_1><ADDRESS_2>University of Alberta</ADDRESS_2><CITY>Edmonton</CITY><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>001 780 492 6611</PHONE_1></ADDRESS></PERSON><PERSON ID="FB72D3DD82E26AA20100F9CCFABFA64F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Rowe</LAST_NAME><SUFFIX>MD, MSc, CCFP (EM), FCCP (BR)</SUFFIX><POSITION>Professor and Research Director</POSITION><EMAIL_1>brian.rowe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Room 1G1.43 Walter C. Mackenzie Health Sciences Centre</ADDRESS_1><ADDRESS_2>8440  112th Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 6707</PHONE_1><PHONE_2>+1 780 407 6761</PHONE_2><FAX_1>+1 780 407 3982</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-27 15:03:17 +0100" MODIFIED_BY="Toby J Lasserson">
<UP_TO_DATE>
<DATE DAY="7" MONTH="8" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="8" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2009-04-27 15:03:47 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-27 15:03:47 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="27" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>Technical issue identified; resolved by programmer </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-04-27 15:03:29 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-04-27 15:03:29 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="8" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Literature search re-run; no new studies identified. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-27 15:03:27 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="7" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="29" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Family Medicine, Universiy of Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Association of Emergency Medicine Research Consortium</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Canadian Institute of Health Research (CIHR)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Garfield Weston Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-07 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-08-07 10:26:27 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-08-07 10:26:27 +0100" MODIFIED_BY="Toby J Lasserson">Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction</TITLE>
<SUMMARY_BODY>
<P>Exercise-induced bronchoconstriction, also commonly called exercise-induced asthma, is associated with symptoms such as cough (locker room cough), wheezing, shortness of breath, and chest tightness following exercise. While an episode is generally self-limiting, it can cause those afflicted to avoid vigorous activity and serious athletes to under-perform by limiting endurance and prolonging recovery time. The combined results from the studies, determined that short-acting beta-agonists inhaled prior to exercise reduced the severity of attacks in both adults and children when compared to mast cell stabilizers alone. In addition, the mast-cell stabilizers were slightly more effective than anticholinergic bronchodilators. Combining short-acting beta-agonists and mast-cell stabilizers was no more effective than the agents administered alone. There were no significant adverse effects reported with the short term use of any of the drugs. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-07 14:04:25 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Exercise-induced bronchoconstriction (or asthma) following strenuous physical exertion is common and can cause sub-optimal performance, symptoms such as cough, dyspnea, wheeze, chest tightness, and can lead people to avoid physical activity. Management focuses on prevention with pre-exercise treatment using various pharmacologic agents. Mast cell stabilizing agents are effective in attenuating exercise-induced bronchoconstriction but their effectiveness compared to bronchodilator agents is unclear. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To quantitatively compare the effects of inhaling a single dose of either mast cell stabiliser - nedocromil sodium or sodium cromoglycate - to a single dose of short acting beta-agonists or anti-cholinergic agents - atropine or ipratropium bromide - prior to a strenuous exercise challenge in participants with asthma who are at least 6 years of age and suffer from reproducible exercise-induced bronchoconstriction. The review also compares the effects between a short acting beta-agonist alone to a combination of a short acting beta-agonist + mast cell stabiliser. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-07 14:04:25 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We searched the Cochrane Airways Group Specialised Register, CENTRAL, Current Contents, review articles, textbooks and reference lists of articles. We also contacted the drug manufacturer and primary authors for additional citations. Searches are current as of August 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing a single prophylactic dose of a mast cell stabiliser to a short acting beta-agonist, anti-cholinergic agent, or a short acting beta-agonist alone to a combination of short acting beta-agonist plus a mast cell stabiliser to prevent exercise-induced bronchoconstriction in asthmatics over six years old. The exercise challenge had to conform to acceptable standards and pulmonary function (PFT) reported as percent decrease from baseline of FEV1 or peak flow. Complete protection (maximum % fall PFT &lt;15% post-exercise) and clinical protection (50% improvement over placebo effect) measures were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial inclusion and quality assessments were conducted independently by two reviewers using standardised forms. A second reviewer confirmed data extraction and calculations. Attempts were made to contact study authors. The pooled estimate involving continuous pulmonary function measures are reported as a weighted mean difference (WMD), dichotomous data as an odds ratio (OR), both with 95% confidence intervals (95%CI) using a random effects model. Heterogeneity tests for pooled results were performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty-four trials (518 participants) conducted in 13 countries between 1976 and 1998 were included. All drugs were effective at attenuating the exercise-induced bronchoconstriction response but to varying degrees even within the same individual. Compared to anti-cholinergic agents, mast cell stabilisers were somewhat more effective at attenuating bronchoconstriction. On average the maximum fall on MCS was reduced to 7.1% compared to 13.8% on AC ( WMD = 6.7%; 95% CI: 3.3 to 10.0), provided more individuals with complete protection (73% vs 56%; OR = 2.2; 95% CI: 1.3 to 3.7) and clinical protection (73% vs 52%; OR = 2.7; 95% CI: 1.1 to 6.4). There were no subgroup differences based on age, severity, or study quality, and no adverse effects were reported for either agent group. When compared to short acting beta-agonists mast cell stabilisers were not as effective at preventing deterioration. On average the maximum fall on MCS was 11.2% compared to 4.3% on beta agonists ( WMD = 6.8%; 95% CI: 4.5 to 9.2). MCS provided fewer individuals with complete protection (66% vs 85%; OR = 0.3; 95% CI: 0.2 to 0.5) or clinical protection (55% vs 77%; OR = 0.4; 95% CI: 0.2 to 0.8). There were no significant subgroup differences based on age, severity, drug, delivery, or study quality. A non-significant difference in side effects was demonstrated with 11% of short acting beta-agonist patients experiencing side effects compared to 3% of those receiving mast cell stabilisers (OR = 0.2; 95% CI: 0.0 to 8.2). Combining mast cell stabilisers with a short acting beta-agonist did not produce significant advantages to pulmonary function over short acting beta-agonists alone. On average the maximum fall on SABA only was reduced to 5.3% compared to 3.5% on the combination ( WMD = 1.8%; 95% CI: -1.1 to 4.6). Beta-agonists alone provided fewer individuals with complete protection (68% vs 80%; OR = 0.5; 95% CI: 0.2 to 1.4) or clinical protection (70% vs 86%; OR=0.4; 95% CI: 0.1 to 1.2) but the difference did not reach significance (p=0.17). There were no subgroup differences.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In a population of stable asthmatics short acting beta-agonists, mast cell stabilisers, or anticholinergics will provide a significant protective effect against exercise-induced bronchoconstriction with few adverse effects. On average, SABAs resulted in more effective attenuation than mast cell stabilisers, while mast cell stabilisers were more effective than anti-cholinergic agents. Combining SABA and mast cell stabilisers may be appropriate in selected cases. The variability in the individual degree of response to these drugs in multi arm trials suggests clinicians and patients work together to identify the most effective prophylactic therapy. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-07 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Acute transient airway narrowing that most often occurs following strenuous physical exercise is referred to as exercise-induced bronchoconstriction (EIB) or exercise induced asthma (EIA) and was first described nearly 2000 years ago. It occurs in 70% to 90% of people with asthma (<LINK REF="REF-Anderson-1985" TYPE="REFERENCE">Anderson 1985</LINK>; <LINK REF="REF-Randolph-1997" TYPE="REFERENCE">Randolph 1997</LINK>), 35 to 40% of people with allergic rhinitis (<LINK REF="REF-McCarthy-1989" TYPE="REFERENCE">McCarthy 1989</LINK>), 10 to 50% of elite athletes (<LINK REF="REF-Mehta-_x0026_-Busse-1997" TYPE="REFERENCE">Mehta &amp; Busse 1997</LINK>; <LINK REF="REF-Rundell-2002" TYPE="REFERENCE">Rundell 2002</LINK>), and an estimated 12% to 15% of the general population (<LINK REF="REF-Spector-1993" TYPE="REFERENCE">Spector 1993</LINK>). </P>
<P>Exercise is one of the most common triggers of an acute asthma attack. The attack is typically provoked by 6 to 15 minutes of continuous exercise of at least 80 to 90% predicted maximum workload (<LINK REF="REF-Godfrey-1987" TYPE="REFERENCE">Godfrey 1987</LINK>; <LINK REF="REF-Weiler-1996" TYPE="REFERENCE">Weiler 1996</LINK>). Airway hyper-reactivity leads to airway narrowing that results in signs of abnormal pulmonary function tests (PFTs), and symptoms of dyspnea, cough, wheeze, chest tightness, premature fatigue, decreased stamina, and prolonged recovery times. Maximum bronchoconstriction usually occurs 3 to 15 minutes post exercise and subsides spontaneously within 20 to 60 minutes (<LINK REF="REF-Virant-1992" TYPE="REFERENCE">Virant 1992</LINK>; <LINK REF="REF-Brudno-1994" TYPE="REFERENCE">Brudno 1994</LINK>). A post-challenge fall of forced expiratory volume in 1 second (FEV1) of 10 -15% or more is diagnostic of EIB (<LINK REF="REF-Beck-1997" TYPE="REFERENCE">Beck 1997</LINK>). Occasionally there is a late phase response (<LINK REF="REF-Chhabra-1998" TYPE="REFERENCE">Chhabra 1998</LINK>) and some people experience a refractory period of up to 3 hours, during which further exercise causes less obstruction (<LINK REF="REF-Gotshall-2002" TYPE="REFERENCE">Gotshall 2002</LINK>).</P>
<P>The severity of the reaction is influenced by several factors - chronic asthma therapy, intensity and duration of activity, environmental conditions, degree of underlying bronchial hyper reactivity, level of physical conditioning, and the time interval since previous exercise (<LINK REF="REF-Rupp-1996" TYPE="REFERENCE">Rupp 1996</LINK>). A 'rescue' bronchodilator agent may be needed if PFT decreases in excess of 30% occur (<LINK REF="REF-Anderson-1985" TYPE="REFERENCE">Anderson 1985</LINK>) and episodes can be severe enough to require emergency treatment. Therefore, EIB is a concern not only to those who suffer from it, but also to those who supervise physical activities.</P>
<P>Keeping physically active contributes to healthy physical and social development but those with EIB may avoid participating in triggering activities (including employment choices) or simply suffer because they don't recognize the abnormal response (<LINK REF="REF-Massie-2002" TYPE="REFERENCE">Massie 2002</LINK>; <LINK REF="REF-Hogshead-1989" TYPE="REFERENCE">Hogshead 1989</LINK>). Therefore the diagnosis and treatment of EIB is important for achieving healthy self-esteem and maximum physical performance. The benefits of successful management can be remarkable at all ages and levels of activity - with treatment, 67 EIB athletes competing at the 1984 Olympics won 41 medals, 15 of them gold (<LINK REF="REF-Pierson-1988" TYPE="REFERENCE">Pierson 1988</LINK>).</P>
<P>The complex pathophysiology underlying EIB continues to stimulate debate; however, it is known that EIB cannot be 'cured' (<LINK REF="REF-Anderson-2000" TYPE="REFERENCE">Anderson 2000</LINK>). Management must focus on prevention, with the aim being symptom free activity. This can be achieved through a combination of pharmacologic and non-pharmacologic interventions. A variety of medications have been shown to prevent or at least reduce the EIB response. The traditional recommendation has been a pre-exercise dose of a short acting bronchodilator (SABA), such as salbutamol (<LINK REF="REF-Virant-1992" TYPE="REFERENCE">Virant 1992</LINK>; <LINK REF="REF-Sly-1984" TYPE="REFERENCE">Sly 1984</LINK>). Mast-cell stabilizing agents, such as nedocromil sodium (NCS) and sodium cromoglycate (SCG), as well as inhaled anticholinergics have also been recommended. A Cochrane meta-analysis (<LINK REF="REF-Spooner-1998" TYPE="REFERENCE">Spooner 1998</LINK>) demonstrated that nedocromil sodium had a statistically and clinically significant effect in attenuating EIB. A subsequent meta-analysis, comparing NCS to SCG (<LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>), found no significant difference between the two when examining effects on pulmonary function, complete protection, clinical protection, or side effect profiles. </P>
<P>The present systematic review seeks to examine the available evidence comparing either of these two mast-cell stabilising agents to short-acting bronchodilator therapies for treating EIB. It also looked at lung function when a mast-cell stabiliser was given in combination with a SABA..</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objectives of this review are threefold: 1) to compare the effect of a prophylactic dose of either NCS or SCG (hereafter designated together as mast cell stabilisers or MCS) to that of an anticholinergic agent (atropine or ipratropium bromide; hereafter designated anticholinergics or AC), 2) to compare the effect of prophylactic doses of MCS to short acting beta-agonists (SABA), and 3) to compare the effect of a prophylactic dose of SABA alone to a combination of SABA + MCS prior to a strenuous exercise challenge in participants with asthma who are at least 6 years of age and suffer from reproducible EIB. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-07 14:04:33 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-08-07 10:27:19 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Only randomised controlled trials were considered for inclusion. Data published in abstract form only were excluded unless the authors could provide a full manuscript for review. Unpublished data was also considered. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All studies on children (=&gt;6 years) and adults (=&gt;17 years) who had a history of EIB, or who demonstrated that they had EIB in a 'control' standardised exercise challenge prior to entry into the trial, were considered. The selection criteria formally defined EIB as a fall from baseline of 10% or greater in FEV1 or PEFR following exercise although all of the included studies required at least a 15% or 20% fall for inclusion into the individual trials. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The focus of this review was on trials in which participants were randomised to receive an MCS agent compared to either an AC, a SABA, or a combination of a SABA + MCS in a single prophylactic dose prior to a standardised exercise challenge test sufficient to trigger EIB. If studies had more than one drug arm, only the comparisons with the drugs under study were included (placebo comparisons, and other combinations were excluded). The following were also excluded: studies that involved delivery via nasal sprays, and trials investigating experimental or numbered drugs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-07 10:27:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All patient outcomes, both subjective and objective, were considered.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-07 10:27:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The primary outcome of interest was the maximum percent fall in pulmonary function, which is the conventional approach to quantifying EIB (<LINK REF="REF-Anderson-1985" TYPE="REFERENCE">Anderson 1985</LINK>). The percent (%) fall index expresses the reduction in lung function after exercise as a percent of the pre-exercise baseline. The formula to calculate the fall index was [maximum % fall PFT = (baseline PFT - lowest post-exercise PFT) / baseline PFT x 100].</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-07 10:27:19 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>The proportion of participants who received complete protection from EIB. As in other EIB reviews (<LINK REF="REF-Spooner-1998" TYPE="REFERENCE">Spooner 1998</LINK>; <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>), a drug was considered to offer complete protection if the maximum % fall index was &lt; 15%.</LI>
<LI>The number of participants who received clinical protection from EIB. As in other EIB reviews (<LINK REF="REF-Spooner-1998" TYPE="REFERENCE">Spooner 1998</LINK>; <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>), a drug was considered to offer clinical protection if PFT values improved by 50% or more over the placebo effect (<LINK REF="REF-ERS-Task-Force-1997" TYPE="REFERENCE">ERS Task Force 1997</LINK>). The formula used to calculate clinical protection was: [clinical protection = (maximum % fall placebo - maximum % fall drug) / maximum % fall placebo x 100]. (<LINK REF="REF-Anderson-1985" TYPE="REFERENCE">Anderson 1985</LINK>).</LI>
<LI>The number and nature of adverse effects experienced.</LI>
<LI>Subjective outcomes involving symptom scores or preference measures.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-07 14:04:33 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-08-07 14:04:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and handsearching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'asthma' were searched using the following terms:</P>
<P>(physical or exercis* or train* or fitness or bronchoconstrict* or bronchospas* or EIB or EIA) AND (nedocromil* OR dscg OR cromo* OR tilade OR intal) AND (beta-agonist* OR "beta agonist*" OR albuterol OR salbutamol OR ventolin OR proventil OR metaproterenol OR alupent OR orciprenalin* OR terbutalin* OR bricanyl OR fenoterol OR reproterol OR procaterol OR anticholinergic* OR atropine OR ipratropium OR atrovent OR Bitolterol OR Tornalate OR Isoetharine* OR Etyprenalinum OR Bronkometer OR Isoetarin OR Pirbuterol OR Pyrbuterol OR Maxair)</P>
<P>The most recent search was carried out in August 2008</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-07 10:28:25 +0100" MODIFIED_BY="Toby J Lasserson">
<P>In addition, Current Contents, reference lists of included studies, review articles and textbooks were searched for relevant citations.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-07 10:29:44 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-08-07 10:28:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A two-step process was employed to select articles:</P>
<P>Phase 1: Two reviewers independently screened the initial searches of all the databases and reference lists to identify potentially relevant citations using title, abstract +/- MeSH headings. </P>
<P>Phase II: The full text of all selected articles was obtained and, using defined eligibility criteria, two independent reviewers selected trials for inclusion in the review. Appropriate members of the CAG screened foreign language articles and abstracted data if an article qualified. Reviewers were not blinded to authors, journal, results, etc. All articles for which there was agreement were included; discussion or a third party adjudication was used to resolve disagreements when necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-07 10:29:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>One reviewer, who used a standard form, extracted data twice and compared results. All data, numeric calculations, and graphic extrapolations were independently confirmed. Reviewers attempted to contact authors for additional papers, confirm data extraction, and to obtain missing data.</P>
<P>Data extraction included the following:<BR/>Methods: study design, method of randomisation, withdrawals, definition of EIB, exercise challenge procedure.<BR/>Population: Country, recruitment, sample size, age, gender, inclusion and exclusion criteria, mean severity on placebo.<BR/>Intervention: delivery device, timing of therapy, agents, dose, and co-intervention.<BR/>Outcomes: PFT, protection, ADRs.<BR/>Notes: Quality score, statistical issues.</P>
<P>The data were evaluated for publication bias using graphical and statistical methods.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-07 10:29:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Quality assessment was carried out using the Cochrane system (<LINK REF="REF-CC-Handbook" TYPE="REFERENCE">CC Handbook</LINK>), which assesses the method of concealment of allocation, and the Jadad 5-point scale that assesses randomisation, blinding, and withdrawals (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Discussion or a third party adjudication was used to resolve disagreements when necessary.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-08-07 10:29:26 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data were entered and analysed using Review Manager (Version 4.1). For continuous variables, a random effects weighted mean difference (WMD) with 95% confidence interval (CI) was calculated for each study. All similar studies were pooled using a random effects model WMD with 95% CI. For dichotomous variables, a random effects odds ratio (OR) with 95% CI was calculated for individual studies. All similar studies were pooled using random effects OR with 95% CI. For pooled effects, heterogeneity was tested using the Breslow-Day test; p &lt; 0.05 was considered statistically significant. A random effects model was selected to provide a more conservative estimate of effect. A sensitivity analysis comparing a fixed effects model with a random effects model was performed.</P>
<P>Our primary intent was to provide a pooled estimate of the mean difference in effect on pulmonary function (PFTs) - either FEV1 or PEFR. Secondarily, we wanted to provide a pooled estimate of the mean difference in PFT related to clinical protection (measured in continuous pulmonary function measures); as well a pooled odds ratio (OR) for obtaining clinical protection, a pooled OR for obtaining complete protection from EIB and, finally, a pooled OR for adverse reactions (ADRs). The latter compared as dichotomous measures.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-08-07 10:29:40 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Where significant heterogeneity existed, the reviewers performed sensitivity analysis based on methodological quality (high Jadad score 3-5 vs. low &lt;3), and the formula used to calculate the per cent fall index.</P>
<P>Subgroup analyses were conducted for children and adults. The reviewers also explored the impact of delivery method, choice of drug, severity of EIB, and recent steroid use. In keeping with previous reviews, mild EIB was defined as a percent fall index of &lt;30% on placebo, moderate to severe EIB as a percent fall of =&gt; 30% (<LINK REF="REF-Spooner-1998" TYPE="REFERENCE">Spooner 1998</LINK>; <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>). When individual patient data were available, the outcomes were calculated from this data and participants who did not demonstrate EIB on placebo were omitted. Though a fall in pulmonary function of 10% is suggestive of EIB, all trialists elected to set their inclusion criteria at 15% or greater; therefore, we used a fall of &lt; 15% post exercise to indicate complete protection.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-07 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-08-07 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2008-08-07 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>Seventy-eight titles and abstracts were selected from the original database search. Four additional citations were identified from the reference lists of relevant publications for a total of eighty-two potentially relevant studies. From the title, abstract, and keywords, two reviewers independently selected 41 (50%) for full text review (kappa 0.92). Nine foreign language studies were screened by CAG members. Searches are updated annually. The last updated search was performed in August 2008. Twenty-four trials are included in this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-08-07 10:32:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Twenty-four studies met the inclusion criteria, 3 were foreign language trials. Collectively, they reported data on 518 participants (M=251; F=162; 7 did not report gender distribution). Thirteen trials studied children age 6-17, while the remaining 11 studied adults 18 or older. Sixteen trials were classified as severe EIB (% fall PFT on placebo =&gt; 30%) while 7 were considered mild EIB and 1 did not report this information. Five trials reported a total of 13 withdrawals for reasons of no EIB on a test run, an asthma exacerbation at time of testing, or a severe response to a non-included drug; all studies excluded withdrawals from their analysis. The exercise challenges involved an inclined treadmill (N=19), free running (N=1), bicycling (N=3) and stair climbing (N=1). All were standardised and met recommended testing criteria (<LINK REF="STD-Eggleston-1972" TYPE="STUDY">Eggleston 1972</LINK>). Since all but 2 studies used the cross-over design (2 were parallel: <LINK REF="STD-Rohr-1987" TYPE="STUDY">Rohr 1987</LINK>; <LINK REF="STD-Vazquez-1984" TYPE="STUDY">Vazquez 1984</LINK>), all participants received all treatments, the total number of participants listed on the MetaView summary screen is nearly double the actual number of participants.</P>
<P>The 24 trials were conducted between 1976 and 1998 in 12 different countries: 3 North America, 17 Europe, 2 Asia, and 2 Australia. Eleven studies compared an MCS to an AC agent. The mast cell stabilising agent most frequently used was sodium cromoglycate (N = 23, dose range 2 - 40mg; 14 used 20mg); one study used 4 mg nedocromil sodium (<LINK REF="STD-de-Benedictis-1998" TYPE="STUDY">de Benedictis 1998</LINK>). The anticholinergic agent of choice was ipratropium bromide (N=8; dose range 120ug - 2 mg); 2 studies (<LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>; <LINK REF="STD-Tashkin-1977" TYPE="STUDY">Tashkin 1977</LINK>) employed atropine 0.2% and 1 (<LINK REF="STD-Neijens-1981a" TYPE="STUDY">Neijens 1981a</LINK>) oxytropium bromide 0.02mg. Twenty studies compared a MCS to a SABA. All used SCG, but several SABAs were tested: 6 fenoterol (dose range 0.1-2mg), 10 salbutamol (dose range 0.2 -2.5mg), 2 terbutaline, 1 reproterol,1 procaterol and 1 isoproterenol. Ten studies compared a SABA to a combination of SCG + SABA. Four studies used fenoterol, 3 salbutamol, 1 terbutaline, and 1 reproterol. The delivery methods also varied (8 nebulised, 5 MDI, 3 spinhaler, and 2 not described) and six studies employed two or more devices. Due to the wide variety in methods used, post-hoc subgroups were created by SABAs used and delivery method to explore the possible effect on outcome. In all cases, there were interesting observations; however, there were too few studies in each category to draw definitive conclusions.</P>
<P>We also performed a post hoc comparison between studies that included inhaled corticosteroid (ICS) users vs. those that excluded all steroid use in at least the past two weeks. The frequency of regular vs. as needed SABA use prior to testing was not reported and therefore not explored. All studies required participants to abstain from taking any bronchodilator for at least 8 hours prior to a challenge, other medications were withheld for longer periods of time.</P>
<SUBSECTION>
<HEADING LEVEL="6">Current asthma medication use</HEADING>
<P>Fourteen of the 24 included trials either excluded or reported that participants were not using oral or inhaled corticosteroids at the time of testing. In six studies steroid use was unclear and the total reported use of ICS in four other studies was 14/49 (29%). Some participants were on theophylline or SCG as well as 'as needed SABA use'. No mention of long acting beta-agonist (LABA) use was reported. All studies required patients to discontinue all current asthma medications using adequate washout periods prior to all challenges. The times recommended for washout of asthma medications are: SABA 6hr. , LABA 24 hr., short acting antihistamines 48hr., long acting antihistamines 1 wk., MCS 6 hr., and up to a few days for inhaled steroids (<LINK REF="REF-Beck-1997" TYPE="REFERENCE">Beck 1997</LINK>; <LINK REF="REF-Anderson-1995" TYPE="REFERENCE">Anderson 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Pulmonary function outcomes</HEADING>
<P>Sixteen trials (9 children, 7 adult) reported the response to treatment using FEV1 (max % fall FEV1=14; % predicted=1; change=1); 8 trials (5 children, 3 adult) used PEFR (max % fall PEFR). Studies were not consistent in reporting all of the outcomes of interest and therefore comparisons combine different numbers of studies. Since the majority of studies reported a percent change from baseline rather than absolute PFT values this review provides pooled estimates of FEV1 and PEFR results using a WMD, random effects model. (Percent change was calculated as {baseline PFT - lowest post exercise PFT/baseline PFT * 100%}). The six trials conducted by A. Bundgaard and colleagues on independent participants calculated a top-bottom index (TBI using the formula {TBI = highest PFT prior to, during or immediately after challenge - lowest PFT post-challenge/ highest PFT before/after challenge} (<LINK REF="STD-Bundgaard-1983p" TYPE="STUDY">Bundgaard 1983p</LINK>). Since this formula consistently provides a higher percent change, they were analysed separately to avoid biasing results and over-estimating the pooled result. One trial (<LINK REF="STD-Zanconato-1990" TYPE="STUDY">Zanconato 1990</LINK>) measured the energy cost of running, gas exchange and ventilation. One study only reported Jones Lability Index results (<LINK REF="STD-Rasmussen-1979" TYPE="STUDY">Rasmussen 1979</LINK>) and these are not included in the analyses.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Using the Cochrane criteria to assess allocation concealment, 3 studies were rated as having "adequate" concealment, all others were given an "unclear" status. </P>
<P>Using Jadad's 5 point validity scale, 2 studies rated 5 (strong), 5 rated 4 (very good), 9 rated 3 (good), 5 rated 2 (poor), and 3 rated 1 (very poor). All studies stated they were randomised; 16 were double-blinded, 5 were evaluator-blind and 3 did not mention blinding. All authors either described dropouts or had none. Most studies lacked a sufficient description of the method of randomisation and/or blinding used.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-07 10:35:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The results will be reported based on the comparisons articulated in the objectives section above.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mast cell stabiliser (NCS or SCG) compared to anticholinergic (AC) agents:</HEADING>
<P>Both MCS and AC agents attenuated the EIB response in the majority of participants; however, MCS afforded a modest advantage over AC. From 8 trials (n = 183) the mean maximum fall in post exercise PFT on MCS decreased to 7.1% compared to 13.8% on AC (WMD = 6.7; 95% CI: 3.3 to 10.0%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Though subgroup comparisons by age and severity favoured MCS, the pooled results between groups were not significantly different:</P>
<P>1. Children vs. adults: the mean maximum fall on MCS in children (n=55) was 9.4% compared to 16.0% on AC (WMD = 6.6%; 95% CI: 1.0 to 12.2%) while the mean maximum fall on MCS in adults (n=128) was 5.8% compared to 12.5% on AC (WMD = 6.7%; 95% CI: 2.5 to 11.0).<BR/>2. Mild vs. moderate-severe EIB: the mean maximum fall on MCS in mild EIB (n=125) was 4.7% compared to 10.6 % on AC (WMD = 5.9%; 95% CI: 2.0 to 9.8%) while the mean maximum fall on MCS in moderate-severe EIB (n=58) was 14.2% compared to 23.4% on AC (WMD = 9.1%; 95% CI: 2.3 to 15.9).<BR/>3. Non-steroid users: the mean maximum fall on MCS (n=56) was 11.2% compared to 19.5% on AC (WMD = 8.4%; 95% CI: 2.5 to 14.3%) The 3 remaining trials in this group of 8 did not report current steroid use and so could not be included in the comparison.</P>
<P>Significantly more participants obtained complete protection on MCS (73%) than AC (56%) agents (OR = 2.2; 95% CI: 1.3 to 3.7). The advantage in obtaining clinical protection was also significant, 73% for MCS compared to 52% for AC (OR = 2.7; 95% CI: 1.1 to 6.4). There were no adverse effects reported in either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">MCS compared to SABA agent:</HEADING>
<P>MCS and SABA also attenuated the EIB response in the majority of participants. In these comparisons SABAs were somewhat more effective at attenuating bronchoconstriction than MCS. From 12 trials (n = 271), the mean maximum fall in post exercise PFT using MCS was 11.2% compared to 4.3% on SABA (WMD = 6.8%; 95% CI: 4.5 to 9.2%, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The pooled result from the 5 studies that calculated a TBI also favoured SABA (WMD = 14.7%; 95% CI: 9.1 to 20.3%).</P>
<P>The subgroup comparison by age favoured SABA but the pooled results between groups was not significantly different. The mean maximum fall on MCS in children (n=91) was 11.9% compared to 4.6% on SABA (WMD = 7.3%; 95% CI: 3.9 to 10.7%) while the mean maximum fall on MCS in adults (n=180) was 10.0% compared to 3.5% on SABA (WMD = 6.4%; 95% CI: 2.7 to 10.1).</P>
<P>The subgroup comparison by severity of EIB indicates that participants with more severe EIB obtain a greater benefit from SABAs than MCS compared to those with milder EIB. The mean maximum fall on MCS in mild EIB (n=136) was 7.5% compared to 3.5% on SABA (WMD = 4.0%; 95% CI: 1.7 to 6.4%) while the mean maximum fall on MCS in moderate-severe EIB (n=135) was 16.2% compared to 5.4% on SABA (WMD = 10.8%; 95% CI: 2.3 to 15.9). The difference between these groups was statistically significant. The participants in the four TBI studies were all classified as moderate-severe (n =65), this WMD = 15.3%; 95% CI: 8.1 to 22.3.</P>
<P>Four trials included only non-steroid users, five did not report steroid use, and in the three remaining trials 26% of participants were taking regular inhaled corticosteroids. The mean maximum fall in non-steroid users on MCS (n=78) was 13.1% compared to 6.7% on SABA (WMD = 6.4%; 95% CI: 3.2 to 9.5%). Since no trials included 100% inhaled steroid users no comparison could be made.</P>
<P>Significantly more participants obtained complete protection using SABA (85%) compared to MCS (66%) agents (OR for MCS = 0.3; 95% CI: 0.2 to 0.5). The difference in obtaining clinical protection also significantly favoured SABA over MCS, 77% vs 55% (OR for MCS = 0.4; 95% CI: 0.2 to 0.8). SABA afforded a mean degree of clinical protection over the placebo response that was 23% greater than MCS agents (WMD: 22.7%; 95% CI: 11.9 to 33.4%). SABA caused significant bronchodilation immediately prior to exercise especially in those with lower lung function at baseline whereas MCS did not.</P>
<P>Comparison 2, outcome 9 provides results by beta-2-agonist subgroup, and outcome 8 compares results by delivery method. Although there are some variations in the pooled results, they are not significant and there are not enough studies in all categories to draw any firm conclusions regarding which drug or delivery method is more effective. Adverse or unpleasant effects were noted in 17/152 (11%) after SABA compared to 4/152 (3%) after MCS. The test for heterogeneity was non-significant for all pooled comparisons, except the ones using the TBI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">SABA compared to combination SABA + SCG:</HEADING>
<P>No statistically or clinically significant advantage was identified when SABA alone was compared to a combination of SABA + MCS; however, in all but one study the point estimate favoured the combination. In 5 trials (n=65) using the percent change index, the mean maximum fall PFT WMD = 1.8%; 95% CI: -1.1 to 4.6%). Using the TBI (4 trials), the pooled WMD =13.4 (95% CI: 7.0 to 19.8%). There were not enough studies in each of the subgroups to draw definite conclusions but the results available indicate no significant differences in comparisons by age (children WMD = 1.8%; 95% CI: -1.3 to 4.9% vs adult WMD = 1.3%; 95% CI: -6.3 to 28.9), or severity (mild EIB WMD = 1.5%: 95% CI: -1.5 to 4.5% vs moderate-severe EIB WMD = -0.5%; 95% CI: -3.3 to 2.3%). Seventy percent of participants obtained clinical protection on SABA alone versus 86% on the combination (OR = 0.4; 95% CI: 0.1 to 1.2). Complete protection was obtained in 68% on SABA compared to 80% using the combination (OR = 0.5; 95% CI: 0.2 to 1.4).</P>
<P>The test for heterogeneity was non-significant for all pooled comparisons, and the results remained stable in sensitivity analyses on quality and fixed versus random effects.</P>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Zanconato et al measured the work effort involved during the exercise challenge (<LINK REF="STD-Zanconato-1990" TYPE="STUDY">Zanconato 1990</LINK>). They reported that both SCG and SABA significantly decreased the energy cost of running, ventilation, oxygen consumption, and tidal volume, and therefore significantly increased the running duration. There was no advantage in one drug over the other in this regard. The authors concluded that asthmatics have higher energy requirements per unit of work when untreated compared to treatment with either agent.</P>
<P>An insufficient number of trials reported the time course of EIB in a consistent manner to compare drugs on the basis of recovery time. No trial reported symptom scores.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-07 10:35:31 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The aim of treatment in EIB is to permit people with asthma to participate in vigorous physical activity and perform at normal or even extraordinary levels without hindrance or lingering symptoms. Several individual studies have been conducted to examine the efficacy of single or combined drugs to attenuate the increased airway resistance caused by exercise. Though some are effective, no one medication has been shown to consistently eliminate EIB. The variability in response within and between individuals at differing times and under circumstances reflects the still poorly understood, complex underlying pathophysiology of EIB (<LINK REF="REF-Anderson-2000" TYPE="REFERENCE">Anderson 2000</LINK>). To date no large study has been performed to compare the most popular of the treatments - bronchodilators and MCS. This review was designed to determine the efficacy and magnitude of these therapies by performing a systematic review of all trials that compared the effects on pulmonary function of three frequently used inhaled drugs - mast cell stabilizers, anticholinergics, short acting beta 2 agents (plus a combination of SABA and MCS).</P>
<P>This meta-analysis of 24 randomised, crossover trials involving 518 adults and children, across 12 countries, over 18 years, provides further support for the use of a single dose of any of the three drugs as a safe and effective pharmaceutical treatment in EIB. The studies reviewed included participants with stable lung function at the time of testing (&gt; 70% predicted values, &lt; 10 - 15% variability between challenges) and despite a variety of concomitant anti-asthma therapies, each individual demonstrated diagnosable EIB in a control test with a fall in FEV1 or PEFR of at least 15% (<LINK REF="REF-Beck-1997" TYPE="REFERENCE">Beck 1997</LINK>). None of the participants in these studies were on oral steroids and only 29% were reported to be on inhaled steroids. It is important to remember that although inhaled steroid use usually reduces the severity, significant EIB can still occur in up to 55% of asthmatics well controlled with ICS use and also those with normal lung function at rest (<LINK REF="REF-Anderson-1995" TYPE="REFERENCE">Anderson 1995</LINK>).</P>
<P>In the comparison of MCS (all used cromoglycate) and anticholinergics (6/9 used ipratropium bromide) the mean maximum fall in pulmonary function was attenuated to less than 15% (7.1% vs. 13.8 % respectively) and the pooled estimate demonstrated that MCSs offer an advantage in the magnitude of 7% (95% CI: 3.3 to 10.0). Whether this degree of improvement was noticed by the participants is not known as preference was not reported in any of the trials. Pooled results showed that 73% vs. 56% obtained complete protection and 73% vs. 52% received clinical protection from MCS over AC. No significant heterogeneity was evident among the pooled trials despite different devices, drugs, doses and timing. Similarly, subgroup analyses based on age and severity failed to identify significant differences between these two medications. Since both categories of drugs do offer complete protection to a large number of people, either would be suitable to recommend based on individual preference.</P>
<P>This meta-analysis also demonstrated that SABAs provide a statistically significant advantage in the percent fall index over MCS in the order of 7% (95% CI: 4.5 to 9.2) though again on average both drugs attenuated the maximum fall to less than 15% (4.3% vs. 11.2% respectively). The response varied little with age, drug, dose, delivery device, or method of calculating the percent falls. Those with more severe EIB did appear to obtain more pulmonary benefit from SABAs over MCS in that the WMD was 4.1% (95% CI:1.7 to 6.4%) in mild EIB and 10.8% (95% CI: 7.4 to 14.2%) in more severe cases. It was not reported whether participants detected this difference or that it affected recovery. The pooled results of nine trials showed 85% received complete protection and 77% clinical protection from SABA compared to 66% and 55% for MCS respectively. Adding a MCS to a SABA may offer a small advantage to some. The pooled estimates of percent fall index or top-bottom index did not indicate any significant differences over a SABA alone and although 80 vs. 68% obtained complete protection this difference was not significant (p=0.46). Twelve studies monitored adverse reactions but only two recorded any. Trials using SABAs did report more side effects (11% vs. 3%, N = 2); however, these were limited to tremor and 'distress' and no patients were forced to withdraw on these grounds. It is hoped that future studies will include measures of preference, symptoms, performance, endurance, etc.</P>
<SUBSECTION>
<HEADING LEVEL="6">Methodological limitations</HEADING>
<P>As with any meta-analysis, the possibilities of publication and selection biases should be considered. A comprehensive search of published literature for potentially relevant studies was conducted, and attempts were made to contact first authors to identify unpublished work. Often publication bias exists when negative trials, indicating no significant differences between drugs, are not published and thus are not included in a review. Many of the trials included in this review did not demonstrate a significant difference between agents. Although it is possible that a selection bias occurred, we employed two independent reviewers for the selection process. We are confident that the studies excluded were done so for appropriate reasons and in a consistent manner.</P>
<P>There are no major issues that would limit the applicability of these results in a similar population but there are a few cautionary notes.</P>
<OL>
<LI>The overall findings may be generalised to people who have asthma and atopy with stable lung function greater than 70% predicted yet exhibited EIB when exercising at a level of sufficient intensity and duration. People with EIB caused by other airway disorders were not studied.</LI>
<LI>All of the challenges took place in laboratories with controlled environments; consequently, the results need to be confirmed outdoors where conditions have greater variability.</LI>
<LI>It is not known how physically fit the participants were.</LI>
<LI>Analyses adjusting for known confounding factors was not possible due to insufficient data. The studies did not provide data or stratify participants based on long term use of anti-inflammatories such as inhaled steroids or MCS, frequency of prior SABA use for EIB, or long acting beta agonist use.</LI>
<LI>The small number of studies in subgroup categories introduces a note of caution, but the concordance among results is reassuring.</LI>
<LI>Most studies in this review used the crossover design and were assessed as being of good to high quality. The concern regarding inclusion of crossover trails in a meta-analysis are three fold: carry-over effects, period effects, and statistical issues. Data were not reported in a manner that allowed us to confirm the presence or absence of a carryover. However, since EIB is a short, transient condition that returns to baseline values within one hour and the agents used are short acting with rapid clearance and few side effects, we believe the potential for carry-over to be negligible. The majority of exercise challenges were conducted on separate days.</LI>
<LI>Period effect comes into play because EIB is a variable condition and it is possible that baseline PFT values could vary prior to each exercise challenge. Individuals could randomly experience a change in baseline airflow values depending on many of the factors discussed earlier. Had there been a period effect in every study, there would be no reason to believe any systematic bias towards any one period. The large number of studies included, coupled with the variations in ages, sex, country, severity, co-intervention, etc. should ensure an equal distribution of period effects if they exist. By averaging the estimates, the period effect would disappear, leaving an unbiased estimate of the treatment contrast (<LINK REF="REF-Senn-1991" TYPE="REFERENCE">Senn 1991</LINK>)</LI>
<LI>All studies were analysed as though they were parallel studies rather than crossover. This along with using a random effects method should ensure that the pooled estimates and confidence intervals are conservative rather than exaggerated .</LI>
<LI>Information related to acceptable randomisation, allocation concealment, and blinded outcome assessment was not adequately reported in many of the studies.</LI>
</OL>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-07 10:35:49 +0100" MODIFIED_BY="Toby J Lasserson">
<IMPLICATIONS_PRACTICE MODIFIED="2008-08-07 10:35:36 +0100" MODIFIED_BY="Toby J Lasserson">
<P>EIB is a complex pathophysiological phenomenon and response to therapy is difficult to predict with certainty. Having normal or even better than normal lung function (trained athletes) at baseline is not a guarantee that severe EIB will not be experienced. Weather conditions, air quality, personal fitness, physical effort , duration, and underlying bronchial hyper reactivity all influence EIB. To a large degree, individualized treatment needs to be developed for each patient using an N of 1 trial approach.<BR/>1) Of the three drug categories reviewed (SABAs, mast cell stabilisers, anticholinergics) SABAs appear to be the most effective over a short duration. Overall, complete protection was experienced by 81% with SABAs, 69% with MCS, and 56% with anticholinergics. SABAs produced a small increase in side effects, which may be annoying but not harmful to the user. The current debate of tolerance to SABA with frequent use was not addressed but must be considered. When EIB is severe enough to require treatment SABAs are clearly the treatment of choice and Dr. Anderson suggests reserving them for rescue purposes if other medications work for an individual (<LINK REF="REF-Anderson-1995" TYPE="REFERENCE">Anderson 1995</LINK>). MCS can be used many times a day without fear of side-effects or tolerance (<LINK REF="REF-Kuzemo-1989" TYPE="REFERENCE">Kuzemo 1989</LINK>).<BR/>2) Combining a SABA and MCS prior to exercise may provide additional benefit to some, but not to all people with EIB.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-07 10:35:49 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Future research should focus on:</P>
<OL>
<LI>Correlating pulmonary benefits with patient preference, symptom scores, endurance and recovery time.</LI>
<LI>Validating the duration of response in both responders and non-responders to each drug.</LI>
<LI>Validating the time course of EIB and return to baseline estimates following treatment.</LI>
<LI>Conducting randomised trials that stratify participants by long term antiinflammatory use or short and long acting beta-agonist use.</LI>
<LI>Determining whether frequent use leads to developing tolerance.</LI>
<LI>Measuring the energy cost of exercise such as in the Zoncato study (<LINK REF="STD-Zanconato-1990" TYPE="STUDY">Zanconato 1990</LINK>).</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank the following people for assistance with translating non English publications - Dr Gianni Ferrara, Celia Almeida, Johannes C van der Wouden, Anthony Chahal, and Toby Lasserson. We would also like to thank the staff at the CAG headquarters at St. George's Hospital Medical School: Karen Blackhall and Toby Lasserson. Finally, the assistance of Dr. Chris Cates (CAG Technical Editor) and Professor Paul Jones (CAG Editor) in the reviewing the manuscript was greatly appreciated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>C Spooner: initiated and conducted review; RS: co-reviewer, protocol development, study selection, quality scoring, editing; BHR: Assigned ARG Editor, co-reviewer, reviewed protocol, editing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2008-08-07 15:48:19 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-08-07 15:46:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1987" MODIFIED="2008-08-07 15:45:50 +0100" MODIFIED_BY="[Empty name]" NAME="Boner 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-08-07 15:45:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Antolini I, Andreoli A, De-Stefano G, Sette L</AU>
<TI>Comparison of the effects of inhaled calcium antagonist verapamil, sodium cromoglycate and ipratropium bromide on exercise-induced bronchoconstriction in children with asthma</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1987</YR>
<VL>146</VL>
<PG>408-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boulet-1889" NAME="Boulet 1889" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boulet LP,Turcotte H, Tennina S</AU>
<TI>Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>5</NO>
<PG>882-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1980" NAME="Bundgaard 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A, Rasmussen FV, Madsen L</AU>
<TI>Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets</TI>
<SO>Allergy</SO>
<YR>1980</YR>
<VL>35</VL>
<NO>8</NO>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983a" NAME="Bundgaard 1983a" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A, Schmidt A</AU>
<TI>Pretreatment of exercise-induced asthma by disodium cromoglycate and fenoterol</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1983</YR>
<VL>64</VL>
<NO>Suppl 128</NO>
<PG>521-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983p" NAME="Bundgaard 1983p" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A, Buch D, Schmidt A, Bach-Mortensen N</AU>
<TI>Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<NO>Suppl 130</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1986neb" NAME="Bundgaard 1986neb" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A</AU>
<TI>Exercise-induced asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1980</YR>
<VL>68</VL>
<NO>Suppl 143</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1986pdr" NAME="Bundgaard 1986pdr" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A</AU>
<TI>Exercise-induced asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1980</YR>
<VL>68</VL>
<NO>Suppl 143</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1990" NAME="Clarke 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clarke PS, Ratowsky DA</AU>
<TI>Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>64</VL>
<PG>187-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Benedictis-1998" NAME="de Benedictis 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Benedictis FM, Tuteri G, Pazzelli P, Solinas LF, Niccoli A, Parente C</AU>
<TI>Combination drug therapy for the prevention of exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma, &amp; Immunology</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>4</NO>
<PG>352-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debelic-1988" NAME="Debelic 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debelic M, Hertel G, Konig J</AU>
<TI>Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorward-1982" NAME="Dorward 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorward AJ, Patel KR</AU>
<TI>A comparison of ketotifen with clemastine, ipratropium bromide and sodium cromoglycate in exercise-induced asthma</TI>
<SO>Clinical Allergy</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gehrke-1986" MODIFIED="2008-08-07 15:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="Gehrke 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-08-07 15:46:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gehrke I, Bohm E, Sybrecht GW</AU>
<TI>Stress-induced asthma--placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two</TI>
<TO>Belastungsinduziertes Asthma--plazebokontrollierter Doppelblind-Vergleich der Pravention mit Fenoterol, DNCG und der Kombination von beiden</TO>
<SO>Prax und Klinik der Pneumologie</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>4</NO>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godfrey-1975" NAME="Godfrey 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey S, Konig P</AU>
<TI>Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children</TI>
<SO>Pediatrics</SO>
<YR>1975</YR>
<VL>56</VL>
<PG>930-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godfrey-1976" NAME="Godfrey 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey S, Konig P</AU>
<TI>Inhibition of exercise-induced asthma by different pharmacological pathways</TI>
<SO>Thorax</SO>
<YR>1976</YR>
<VL>31</VL>
<PG>137-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neijens-1981a" NAME="Neijens 1981a" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neijens HJ, Wesselius T, Kerrebijn KF</AU>
<TI>Exercise-induced bronchoconstriction as an expression of bronchial hyperreactivity: a study of its mechanisms in children</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>517-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obata-1993" NAME="Obata 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obata T, Matsuda S, Akasawa A, Iikura Y</AU>
<TI>Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children</TI>
<SO>Annals of Allergy</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>2</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichaipat-1995" NAME="Pichaipat 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichaipat V, Tongpenyai Y, Nerntong T, Sriprapachiranont C</AU>
<TI>The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1995</YR>
<VL>78</VL>
<NO>10</NO>
<PG>505-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohr-1987" NAME="Rohr 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohr AS, Siegel SC, Katz RM, Rachelefsky GS, Spector SL, Lanier R</AU>
<TI>A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm</TI>
<SO>Annals of Allergy</SO>
<YR>1987</YR>
<VL>59</VL>
<PG>107-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spada-1985" NAME="Spada 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spada EL, Donner CF, Meriggi A, Vecchio C</AU>
<TI>Pharmacological prevention of exercise-induced asthma</TI>
<TO>Prevenzione farmacologica dell'asma indotto da esercizio fisco</TO>
<SO>Minerva Pneumologica</SO>
<YR>1985</YR>
<VL>24</VL>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svenonius-1988" NAME="Svenonius 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svenonius E, Arborelius M, Wiberg R, Ekberg P</AU>
<TI>Prevention of exercise-induced asthma by drugs inhaled from metered aerosols</TI>
<SO>Allergy</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>4</NO>
<PG>252-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1978" NAME="Thompson 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson NC, Patel KR, Kerr JW</AU>
<TI>Sodium cromoglycate and ipratropium bromide in exercise-induced asthma</TI>
<SO>Thorax</SO>
<YR>1978</YR>
<VL>33</VL>
<PG>694-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tullett-1982" NAME="Tullett 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tullett WM, Patel KR, Berkin KE, Kerr JW</AU>
<TI>Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma</TI>
<SO>Thorax</SO>
<YR>1982</YR>
<VL>37</VL>
<PG>737-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vazquez-1984" NAME="Vazquez 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez C, Fidalgo I, Virto MC, Labayru MT, Casas C</AU>
<TI>Efficacy of disodium cromoglycate, salbutamol and ipratropium bromide on the inhibition of exercise-induced bronchospasm</TI>
<TO>Efectividad del cromoglicato disodico, salbutamol y bromuro de ipratropio en la inhibicion de broncospasmo inducido por ejercicio normales</TO>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>8</NO>
<PG>756-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woolley-1990" NAME="Woolley 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolley M, Anderson AD, Quigley BM</AU>
<TI>Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>97</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanconato-1990" NAME="Zanconato 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanconato S, Baraldi E, Santuz P, Magagnin G, Zacchello F</AU>
<TI>Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>4</NO>
<PG>240-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-07 15:48:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1979" NAME="Bauer 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer X</AU>
<TI>Concerning the therapy of exercise-induced asthma</TI>
<TO>Ur Therapie Des Belastungsinduzierten Asthma Bronchiale</TO>
<SO>Praxis und Klinik der Pneumologie</SO>
<YR>1979</YR>
<VL>33</VL>
<NO>6</NO>
<PG>791-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1981" NAME="Bauer 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baur X</AU>
<TI>Bronchial asthma induced by exercise</TI>
<SO>Deutsch Medizinische Wochenschrift</SO>
<YR>1981</YR>
<VL>106</VL>
<NO>10</NO>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1984" NAME="Boner 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Zamo CR, Marchiori MM, Biancotto R</AU>
<TI>Comparison of nebulized ipratropium, salbutamol and cromoglicate solutions, cromoglicate inhaled powder, theophylline elixir and placebo in exercise induced asthma of the children</TI>
<TO>Confronto fra Nebulizzazione di Ipratropio, Salbutamolo E Cromoglicato In Soluzione, Cromoglicato In Polvere Inalabile, Teofillina Elisir E Placebo Nell'asma Da Esercizio Dei Bambini</TO>
<SO>Giornale Italiano Delle Malattie del Torace</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>6</NO>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983" NAME="Bundgaard 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A</AU>
<TI>Exercise-induced asthma - laboratory observations</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>64</VL>
<NO>Suppl 128</NO>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceugniet-1997" MODIFIED="2008-08-07 15:48:19 +0100" MODIFIED_BY="[Empty name]" NAME="Ceugniet 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-07 15:48:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceugniet F, Cauchefer F, Fragneaud C, Evano-Celli I</AU>
<TI>Prophylactic treatment of exercise-induced asthma in children: Salmeterol or sodium cromoglycate single dose before exercise?</TI>
<TO>Traitment preventif de l'asthme induit par l'exercise chez le grand enfant: salmeterol ou cromoglycate de sodium en dose unique avant l'effort?</TO>
<SO>Annales de Pediatrie</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>9</NO>
<PG>625-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-1984" NAME="Cummings 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings NP, Strunk RC</AU>
<TI>Combination drug therapy in children with exercise-induced bronchospasm</TI>
<SO>Annals of Allergy</SO>
<YR>1984</YR>
<VL>53</VL>
<NO>5</NO>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cree-1980" NAME="De Cree 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cree J, Verhaegen H, Geukens H</AU>
<TI>The comparative effects of oxatomide, placebo and sodium cromoglycate</TI>
<SO>Clinical Trials Journal</SO>
<YR>1980</YR>
<VL>17</VL>
<NO>3</NO>
<PG>84-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eggleston-1972" NAME="Eggleston 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggleston PA, Bierman CW, Pierson WE, Stamm SJ, Van Arsdel PP</AU>
<TI>A double-blind trial of the effect of cromolyn sodium on exercise-induced bronchospasm</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1972</YR>
<VL>50</VL>
<NO>1</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gimeno-1985" NAME="Gimeno 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gimeno F, van Veenen R, Steenhuis EJ, Berg WC</AU>
<TI>Comparison of disodium cromoglycate, terbutaline and thiazinamium in the prevention of exercise-induced asthma and its relation to non-specific bronchial responsiveness</TI>
<SO>Respiration</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>2</NO>
<PG>108-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerin-1992" NAME="Guerin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerin JC, Brambilla C, Godard P, De Muizon H, Aubert B, Bons J</AU>
<TI>Prolonged protection against exercise-induced bronchoconstriction: Salmeterol as compared to sodium cromoglycate</TI>
<TO>Protection prolongee du bronchospasme a l'effort: salmeterol versus cromoglycate de sodium</TO>
<SO>Revue des Maladies Respiratoires</SO>
<YR>1992</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>R27-R30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1986" NAME="Johnson 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson CE, Belfield PW, Davis S, Cooke NJ, Spencer A, Davies JA</AU>
<TI>Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol</TI>
<SO>Thorax</SO>
<YR>1986</YR>
<VL>41</VL>
<PG>290-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joppich-1987" NAME="Joppich 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joppich R</AU>
<TI>Comparison of the effects of Reproterol, oxitropiumbromide, DNCG, and theophylline in the treatment of exercise induced bronchoconstriction</TI>
<TO>Vergleich der wirkungen von reproterol, oxitropoiumbromid, DNCG und theophyllin auf das anstrengungs-asthma bei kinder</TO>
<SO>Atemweg und Lungenkrankheiten</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>9</NO>
<PG>453-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neijens-1981b" NAME="Neijens 1981b" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neijens HJ, Wesselius TR, Kerrebijn KF</AU>
<TI>Pharmacologic modification of effort dyspnea in children with CARA</TI>
<TO>Farmacologische beinvloeding van kortademigheid door inspanning bij kinderen met CARA Farmacologische beinvloeding van kortademigheid door inspanning bij kinderen met CARA</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1981</YR>
<VL>125</VL>
<NO>32</NO>
<PG>1277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rachelefsky-1978" NAME="Rachelefsky 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rachelefsky GS, Tashkin DP, Katz RM, Kershnar H, Siegel SC</AU>
<TI>A comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1978</YR>
<VL>73</VL>
<NO>Suppl 6</NO>
<PG>1017-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1979" NAME="Rasmussen 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen FV, Madsen L, Bundgaard A</AU>
<TI>Combined effect of an anticholinergic drug ipratropium bromide and disodium cromoglycate in exercise induced asthma</TI>
<SO>Scandinavian Journal of Respiratory Disease</SO>
<YR>1979</YR>
<NO>Suppl 103</NO>
<PG>159-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringel-1982" NAME="Ringel 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ringel KP, el Nur AR, Karg F</AU>
<TI>FPL 52758 and disodium cromoglycate (INTAL) in exercise-induced infantile bronchoconstriction</TI>
<SO>Zeitschrift fur Erkrankungen der Atmungsorgane</SO>
<YR>1982</YR>
<VL>159</VL>
<NO>1</NO>
<PG>50-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spada-1984" NAME="Spada 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spada EL, Donner CF, Fracchia C, Ioli F, Patessio A, Vecchio C</AU>
<TI>A comparative evaluation of salbutamol, disodium cromoglycate and ipratropium bromide in preventing exercise-induced asthma (EIA)</TI>
<SO>Respiration</SO>
<YR>1984</YR>
<VL>46</VL>
<NO>Suppl 1</NO>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabas-1985" NAME="Tabas 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabas A, Rodriguez A, Lobera T, Dieguez I, Oehling A</AU>
<TI>Carbuterol, salbutamol and DSCG in exercise-induced asthma</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>6</NO>
<PG>493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tashkin-1977" NAME="Tashkin 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tashkin DP, Katz RM, Kerschnar H, Rachelefsky GS, Siegel SC</AU>
<TI>Comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1977</YR>
<VL>39</VL>
<PG>311-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verini-1983" NAME="Verini 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verini M, Chiarelli F, Di Tullio A, Morgese G, Pallotta R</AU>
<TI>Pharmacological prevention of exercise-induced bronchospasm. Analysis of literature and evaluation of disodium cromoglycate, fenoterol and ipatroprium bromide in a group of children</TI>
<SO>La Pediatria Medica e Chirurgica</SO>
<YR>1983</YR>
<VL>5</VL>
<PG>501-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woolley-1988" NAME="Woolley 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolley MJ</AU>
<TI>The duration of action of terbutaline and sodium cromoglycate alone and in combincation on exercise-induced asthma (EIA)</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1988</YR>
<VL>18</VL>
<NO>3</NO>
<PG>538</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Anderson-1985" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anderson 1985" NOTES="&lt;p&gt;.Anderson SD: Issues in exercise-induced asthma. J Allergy Clin Immunol 1985;76:6:763-72.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:51 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD</AU>
<TI>Issues in exercise-induced asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1985</YR>
<VL>76</VL>
<NO>6</NO>
<PG>763-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1995" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anderson 1995" TYPE="BOOK_SECTION">
<AU>Anderson SD</AU>
<TI>Specific problems: Exercise-induced asthma (Chapter 34)</TI>
<SO>Manual of Asthma Management</SO>
<YR>1995</YR>
<PG>621-43</PG>
<ED>O'Byrne PO &amp; Thompson NC</ED>
<PB>WB Sanders Company Ltd</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2000" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anderson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Daviskas E</AU>
<TI>The mechanism of exercise-induced asthma is...</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>3</NO>
<PG>453-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATS-1993" NAME="ATS 1993" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>Guidelines for the evaluation of impairment/disability in patients with asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>147</VL>
<PG>1056-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1997" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Beck 1997" TYPE="BOOK_SECTION">
<AU>Beck KC</AU>
<TI>Evaluating exercise capacity and airway function in the athlete (Chapter 2)</TI>
<SO>Allergic and Respiratory Disease in Sports Medicine</SO>
<YR>1997</YR>
<PG>35-64</PG>
<ED>Weiler JM</ED>
<PB>Marcel Dekker, Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boner-1988" NAME="Boner 1988" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Vallone G, Peroni DG, Piacentini GL, Gaburro D</AU>
<TI>Efficacy and duration of action of placebo responses in the prevention of exercise-induced asthma in children</TI>
<SO>Journal of Asthma</SO>
<YR>1988</YR>
<VL>25</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brudno-1994" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Brudno 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brudno DS, Wagner JM, Rupp NT</AU>
<TI>Length of postexercise assessment in the determination of exercise-induced bronchospasm</TI>
<SO>Annals of Allergy</SO>
<YR>1994</YR>
<VL>73</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CC-Handbook" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="CC Handbook" NOTES="&lt;p&gt;Mulrow CD, Oxman AD (eds). Analysing and presenting results. Cochrane Collaboration Handbook [updated 1 March 1997]; Section 8: In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 1996-. Updated quarterly.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:51 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="OTHER">
<AU>Mulrow CD, Oxman AD (editors)</AU>
<TI>Analysing and presenting results. Cochrane Reviewers' Handbook [updated March 1997]; Section 8</TI>
<SO>In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chhabra-1998" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Chhabra 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chhabra SK, Ojha UC</AU>
<TI>Late asthmatic response in exercise-induced asthma</TI>
<SO>Annals of Allergy Asthma &amp; Immunology</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>4</NO>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eggleston-1984" NAME="Eggleston 1984" NOTES="&lt;p&gt;Eggleston PA: Methods of exercise challenge. J Allergy Clin Immunol 1984;73:666-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eggleston PA</AU>
<TI>Methods of exercise challenge</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>666-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1996" MODIFIED="2008-08-07 10:40:26 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ernst 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ernst P, Fitzgerald JM, Spier S</AU>
<TI>Canadian Asthma consensus Conference: Summary of recommendations</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>2</NO>
<PG>89-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ERS-Task-Force-1997" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ERS Task Force 1997" TYPE="JOURNAL_ARTICLE">
<AU>ERS Task Force</AU>
<TI>Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>2662-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Godfrey-1987" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Godfrey 1987" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey S, Bar-Yishay E</AU>
<TI>Exercise-induced asthma revisited</TI>
<SO>Respiratory Medicine</SO>
<YR>1993</YR>
<VL>87</VL>
<PG>331-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gotshall-2002" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Gotshall 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gotshall R</AU>
<TI>Exercise-induced bronchoconstriction</TI>
<SO>Drugs</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>12</NO>
<PG>1725-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogshead-1989" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Hogshead 1989" TYPE="BOOK">
<AU>Hogshead N, Couzens GS</AU>
<SO>Asthma and Exercise</SO>
<YR>1989</YR>
<PB>Henry Holt and Company</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Contr Clin Trials 1996;17:1-12&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:51 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carrol D, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2000" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Kelly 2000" TYPE="COCHRANE_REVIEW">
<AU>Kelly K, Spooner CH, Rowe BH</AU>
<TI>Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002731. DOI: 10.1002/14651858.CD002731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kuzemo-1989" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Kuzemo 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kuzemo JA</AU>
<TI>Twenty years of sodium cromoglycate treatment: a short review</TI>
<SO>Respiratory Medicine</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>Suppl</NO>
<PG>11-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Massie-2002" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Massie 2002" TYPE="JOURNAL_ARTICLE">
<AU>Massie J</AU>
<TI>Exercise-induced asthma in children</TI>
<SO>Paediatric Drugs</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>4</NO>
<PG>267-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCarthy-1989" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="McCarthy 1989" NOTES="&lt;p&gt;McCarthy P. Wheezing and breezing through exercise-induced asthma. Phys Sportsmed 1989:17(7):125-30.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy P</AU>
<TI>Wheezing and breezing through exercise-induced asthma</TI>
<SO>Physician and Sports medicine</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>7</NO>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-_x0026_-Busse-1997" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mehta &amp; Busse 1997" NOTES="&lt;p&gt;Mehta H &amp;amp; Busse WW. Prevalence of exercise-induced asthma in the athlete. Chpt 4 in: Allergic and Respiratory Disease in Sports Medicine. 1997. Weiler JM (ed) . New York: Marcel Dekker, Inc.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK_SECTION">
<AU>Mehta H, Busse WW</AU>
<TI>Prevalence of exercise-induced asthma in the athlete. (Chapter 4)</TI>
<SO>Allergic and Respiratory Disease in Sports Medicine</SO>
<YR>1997</YR>
<ED>Weiler JM</ED>
<PB>Marcel Dekker, Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nemet-2000" NAME="Nemet 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nemet D, Wolach B, Yacobovich J, Eliakim A</AU>
<TI>Exercise in childhood asthma: provoking agent, diagnostic tool and therapeutic measure</TI>
<SO>Israel Medical Association Journal</SO>
<YR>2000</YR>
<VL>2</VL>
<NO>2</NO>
<PG>99-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pierson-1988" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pierson 1988" NOTES="&lt;p&gt;Pierson WE, Voy RO: Exercise-induced bronchospasm in the XXIII Summer Olympic Games. N Engl Region Proc 1988;9:209-13&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Pierson WE, Voy RO</AU>
<TI>Exercise-induced bronchospasm in the XXIII summer Olympic games</TI>
<SO>New England and Regional Allergy Proceedings</SO>
<YR>1988</YR>
<VL>9</VL>
<NO>3</NO>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randolph-1997" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Randolph 1997" NOTES="&lt;p&gt;Randolph C. Exercise-induced asthma:Update on pathophysiology, clinical diagnosis, and treatment. Curr Probl Pediatr 1997;27:53-77.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Randolph C</AU>
<TI>Exercise-induced asthma:Update on pathophysiology, clinical diagnosis, and treatment</TI>
<SO>Current Problems in Pediatrics</SO>
<YR>1997</YR>
<VL>27</VL>
<PG>53-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rundell-2002" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rundell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rundell K, Jenkinson D</AU>
<TI>Exercise-induced bronchospasm in the elite athlete</TI>
<SO>Sports Medicine</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>9</NO>
<PG>583-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rupp-1996" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rupp 1996" NOTES="&lt;p&gt;Rupp NT: Diagnosis and management of exercise-induced asthma. Phys Sportsmed 1996;24:1:77-87.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Rupp NT</AU>
<TI>Diagnosis and management of exercise-induced asthma</TI>
<SO>Physician and Sportsmedicine</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>1</NO>
<PG>77-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Santanello-1999" NAME="Santanello 1999" TYPE="JOURNAL_ARTICLE">
<AU>Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL</AU>
<TI>What are minimal important changes for asthma measures in a clinical trial?</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senn-1991" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Senn 1991" TYPE="JOURNAL_ARTICLE">
<AU>Senn S, Hildebrand H</AU>
<TI>Crossover trials, degrees of freedom, the carryover problem and its dual</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>1361-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sly-1984" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Sly 1984" NOTES="&lt;p&gt;Sly RM: Beta-adrenergic drugs in the management of asthma in athletes. J Allergy Clin Immunol 1984;73:680-5&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Sly RM</AU>
<TI>Beta-adrenergic drugs in the management of asthma in athletes</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>680-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spector-1993" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Spector 1993" NOTES="&lt;p&gt;Spector SL: Update on exercise-induced asthma. Ann Allergy 1993;71:571-7.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Spector SL</AU>
<TI>Update on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1993</YR>
<VL>71</VL>
<PG>571-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spooner-1998" MODIFIED="2008-08-08 12:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Spooner 1998" TYPE="COCHRANE_REVIEW">
<AU>Spooner CH, Saunders LD, Rowe BH</AU>
<TI>Nedocromil sodium for preventing exercise-induced bronchoconstriction</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001183. DOI: 10.1002/14651858.CD001183."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Virant-1992" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Virant 1992" NOTES="&lt;p&gt;Virant FS. Exercise-induced bronchospasm: Epidemiology, pathophysiology, and therapy. Med Sci Sports Exerc 1992;24:851-5.&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 12:34:50 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Virant FS</AU>
<TI>Exercise-induced bronchospasm: epidemiology, pathophysiology, and therapy</TI>
<SO>Medicine and Science in Sports &amp; Exercise</SO>
<YR>1992</YR>
<VL>24</VL>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiler-1996" MODIFIED="2008-08-08 12:34:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Weiler 1996" TYPE="JOURNAL_ARTICLE">
<AU>Weiler JM</AU>
<TI>Exercise-induced asthma: a practical guide to definitions, diagnosis, prevalence, and treatment</TI>
<SO>Allergy and Asthma Proceedings</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>6</NO>
<PG>315-25</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-04-27 15:05:07 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-04-27 15:05:07 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-07 10:35:59 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Boner-1987">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: Fall FEV1=&gt;20%<BR/>Exercise challenge: inclined treadmill x 6 min, 90% predicted maximum HR. <BR/>4 challenges in 4 consecutive days, same time of day. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Recruitment: Volunteers from home for asthmatics<BR/>Sample size: 15; M =10, F=5.<BR/>Mean age: 11.7y sd 14<BR/>Inclusion: Hx of asthma and EIB, all allergic, no CS in past 2 mo., all &gt; 80% predicted normal.<BR/>Exclusion: hypotension, sick sinus syndrome, AV-block,<BR/>Mean severity on placebo: max fall FEV1=40.9% sd 17.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-07 10:35:57 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Delivery method: nebuliser<BR/>Time administered pre-challenge: 30 min<BR/>Mast cell agent/dose: SCG 20mg<BR/>Anticholinergic/dose: IB 500ug<BR/>Concomitant meds stopped: BDs x 12 hr., others 24h - 1 wk.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-07 10:35:59 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: none were seen</P>
<P>Excluded: Verapamil results</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: results calculated from IPD<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-07 10:36:23 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Boulet-1889">
<CHAR_METHODS MODIFIED="2008-08-07 10:36:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 1 withdrawal (exacerbation)<BR/>Def'n EIB: Fall FEV1 &gt;10%<BR/>Exercise challenge: inclined treadmill x 6 min, 90% predicted maximum HR.<BR/>11 challenges in 6 wks. q2 days, same time of day.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada<BR/>Recruitment: volunteers<BR/>Sample size: 11; M=4, F=7.<BR/>Mean age: 30y sd 10.9<BR/>Inclusion: Hx asthma (ATS criteria) &amp; EIB, none on OCS, 4/11 on ICS &gt; 65% predicted, all used B2 prn, 5 on theophylline.<BR/>Exclusion: CV disease, unstable asthma, URTI.<BR/>Mean severity on placebo: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI/spacer<BR/>Time administered pre-challenge: 30 min<BR/>Mast cell agent/dose: SCG 4 mg<BR/>Beta2 agonist/dose: salbutamol 200ug<BR/>Anticholinergic/dose: IB 80 ug<BR/>Concomitant meds stopped: 8-24 hrs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes: <BR/>Clinical protection<BR/>ADRs: NR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4<BR/>Statistical issues: none<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-07 10:36:40 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Bundgaard-1980">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: Fall FEV1&gt;20%<BR/>Exercise challenge: 3 periods free running 2min + 1min rest, HR&gt;160.<BR/>5 challenges on 5 consecutive days, same time of day.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Recruitment: Asthma clinic<BR/>Sample size: 18; M=7, F=11.<BR/>Mean age: 30.5y sd 7.6<BR/>Inclusion: Hx asthma, 17/18 had allergies, normal heart function and chest Xrays, 3/18 were smokers, none on OCS.<BR/>Exclusion: NR<BR/>Mean severity on placebo: Max fall PEFR 33.5%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-07 10:36:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Delivery method: nebuliser<BR/>Time administered pre-challenge: 30-45 min<BR/>Mast cell agent/dose: SCG 20 mg<BR/>Beta2 agonist/dose: fenoterol 2 mg<BR/>Anticholinergic/dose: IB 0.5 mg<BR/>Combined SCG/IB 20mg/0.5 mg<BR/>Concomitant meds stopped: x 24 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-07 10:36:40 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Reported outcomes:<BR/>PEFR: maximum % fall PEFR<BR/>based on top-bottom index .<BR/>ADRs: tremor, 'distress'</P>
<P>Excluded: combination SCG/IB results and oral medication results.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: Values estimated from graphs. Error bars = 2 SEM. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bundgaard-1983a">
<CHAR_METHODS>
<P>Methods: RCT,(table of random numbers) DB, X-over, double-dummy<BR/>Withdrawals: 0<BR/>Def'n EIB: Fall PEFR =&gt;20% <BR/>Exercise challenge: inclined treadmill x 6 min. HR &gt; 160. <BR/>4 challenges in 7 days. Same time of day. T=23C, RH=45%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Recruitment: N/R<BR/>Sample size: 15; M/F NR .<BR/>Mean age: 33y (21-46)<BR/>Inclusion: Hx Asthma, lung function &gt;50% predicted. All used B2 agonists prn. None on systemic CS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: Max fall PEFR 33.0% sd 15.49</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: spinhaler Time administered pre-challenge: 30 min Mast cell agent/dose: SCG 20 mg Beta2 agonist/dose: fenoterol 0.4 mg Combintion SCG/fen 20mg/0.4 mg Concomitant meds stopped: B2 x 8 hr, others x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: mean% fall PEFR based on top-bottom index .<BR/>ADRs. None were observed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4 Statistical issues: Data from text.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bundgaard-1983p">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over, double-dummy<BR/>Withdrawals: 0<BR/>Def'n EIB: Fall PEFR =&gt;20% <BR/>Exercise challenge: inclined treadmill x 6 min. HR &gt; 160. <BR/>4 challenges in 7 days. Same time of day. T=23C, RH=45%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Recruitment: volunteers from clinic<BR/>Sample size: 17; M= 7, F= 10.<BR/>Mean age: 12y (range 9-14)<BR/>Inclusion: Hx Asthma, stable asthma, reproducible EIB. All used B2 agonists. None on CS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: Max fall PEFR =27.0% sd 8.25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: spinhaler<BR/>Time administered pre-challenge: 30 min<BR/>Mast cell agent/dose: SCG 20 mg<BR/>Beta2 agonist/dose: fenoterol 0.4 mg<BR/>Combintion SCG/fen 20mg/0.4 mg</P>
<P>Concomitant meds stopped: B2 x 8 hr, others x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: mean% fall PEFR based on top-bottom index .<BR/>ADRs. None were observed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4<BR/>Statistical issues: Data from text. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bundgaard-1986neb">
<CHAR_METHODS>
<P>Methods: RCT (4x4 William's Square), DB, X-over (conducted 2 studies same protocol, different participants )<BR/>Withdrawals: 0<BR/>Def'n EIB: N/R but mean fall PFT 30% on placebo<BR/>Exercise challenge: inclined treadmill x 6 min consistent settings, <BR/>8 challenges 8 days T=23C, RH=50%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Recruitment: N/R<BR/>Sample size: 16 children; M/F N/R<BR/>Mean age: N/R<BR/>Inclusion: lung function&gt;50% predicted, none on OCS, 4/6 on ICS.<BR/>Exclusion: <BR/>Mean severity on placebo: max fall PEFR 31.0% sd 16.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: nebulizer <BR/>Time administered pre-challenge: 10 min<BR/>Mast cell agent/dose: SCG 20mg <BR/>Beta2 agonist/dose: 2.5mg Combined SCG/B2 20mg/2.5 mg </P>
<P>Concomitant meds stopped: oral meds x 24 hrs. inhaled meds x 8 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: maximum % fall based on top-bottom index<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4<BR/>Statistical issues: sd estimated from SEM bars on graphs<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bundgaard-1986pdr">
<CHAR_METHODS>
<P>Methods: RCT (4x4 William's Square), DB, X-over (same protocol as Bundgaard 86n, independent participants)<BR/>Withdrawals: 0<BR/>Def'n EIB: N/R but mean fall PFT 30% on placebo<BR/>Exercise challenge: inclined treadmill x 6 min consistent settings, <BR/>8 challenges in 8 days. T=23C, RH=50%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Recruitment: N/R<BR/>Sample size: 16 children; M/F N/R<BR/>Mean age: N/R<BR/>Inclusion: lung function&gt;50% predicted, none on OCS, 4/16 on ICS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: max fall PEFR 30% sd 11.43</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: spinhaler<BR/>Time administered pre-challenge: 10 min<BR/>Mast cell agent/dose: SCG 20mg capsule<BR/>Beta2 agonist/dose: salbutamol 0.4 mg capsule<BR/>Combined SCG/B2: 20mg/0.4 mg </P>
<P>Concomitant meds stopped: oral meds x 24 hrs. inhaled meds x 8 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: maximum % fall based on top-bottom index<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4<BR/>Statistical issues: sd estimated from SEM bars on graphs<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-27 15:04:13 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Clarke-1990">
<CHAR_METHODS>
<P>Methods: RCT (Latin Square), DB, double dummy, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1 =&gt;15%<BR/>Exercise challenge: inclined treadmill x 6 min consistent settings, HR=150.<BR/>8 challenges over 2 wks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia<BR/>Recruitment: voluneers from clinic<BR/>Sample size: 20: M=14, F=6.<BR/>Mean age: 29.4y<BR/>Inclusion: Hx asthma, steroid use not reported<BR/>Exclusion: N/R<BR/>Mean severity on placebo: max fall FEV1 15%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: Spinhaler/MDI double dummy<BR/>Time administered pre-challenge: 10 min<BR/>Mast cell agent/dose: SCG 20 mg Beta2 agonist/dose: fenoterol 100ug Concomitant meds stopped: x 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: none were seen</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-27 15:04:13 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Jadad score: 5<BR/>Statistical issues: SDs imputed from weighted average of other included studies.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-de-Benedictis-1998">
<CHAR_METHODS>
<P>Methods: RCT, DB, Double dummy, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: Max fall FEV1=&gt;15%<BR/>Exercise challenge: inclined treadmill x 6 min. HR=85% of max predicted, consistent settings, <BR/>3 challenges in 10 days, same time of day. T=23C, RH=44-57%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Recruitment: volunteers from asthma clinic<BR/>Sample size: 12; M=9, F=3.<BR/>Mean age: 10.0 y sd 2.0<BR/>Inclusion: Hx asthma (ATS criteria), all on treatment with various anti-asthma drugs, some on ICS. &gt;70% predicted, BL values &gt;80% predicted. <BR/>Exclusion: URTI within 4 wks, variability &gt;10% between tests<BR/>Mean severity on placebo: max fall FEV1 31.0% sd 14.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI<BR/>Time administered pre-challenge: 20 min<BR/>Combination Mast cell agent/dose: NCS 4 mg/Salbutamol 200ug<BR/>Beta2 agonist/dose: salbutamol 200ug</P>
<P>Concomitant meds stopped: x 12 hrs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes: <BR/>FEV1: maximum % fall FEV1<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: none were seen</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 4<BR/>Statistical issues: IPD reported and used to calculate clinical protection. <BR/>Patient 5 deleted as no EIB on placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Debelic-1988">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: Max fall FEV1 =&gt;20%<BR/>Exercise challenge: free running x 6 min. same time of day. HR 160-180.<BR/>4 challenges in 4 test days. T=18-20C,</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Recruitment: N/R<BR/>Sample size: 16; M/F: N/R<BR/>Mean age: 13.8 (8-20yrs)<BR/>Inclusion: Hx asthma, all allergic, reproducible EIB, PFT =&gt;70% predicted. None on CS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: max fall FEV1 43%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI<BR/>Time administered pre-challenge: 15 min<BR/>Mast cell agent/dose: SCG 2mg<BR/>Beta2 agonist/dose: reproterol 1mg<BR/>Combination SCG/reproterol 2mg/1mg<BR/>Concomitant meds stopped: x 12 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: none were observed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: Values calculated from IPD. Patient 13, 14 omitted-no EIB on placebo.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-07 10:38:22 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Dorward-1982">
<CHAR_METHODS MODIFIED="2008-08-07 10:38:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Methods: RCT, SB, double-dummy, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1=&gt;25%<BR/>Exercise challenge: inclined treadmill x8 min, consistent settings, HR 170-180.<BR/>T=20-22C, RH=30-50%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Recruitment: volunteers<BR/>Sample size: 7; M=2, F=5<BR/>Mean age: 24y sd 18.39 <BR/>Inclusion: Hx allergic asthma, all were non-smokers. <BR/>Exclusion: OCS or ICS users<BR/>Mean severity on placebo: max fall FEV1 47% sd 6.95</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-07 10:38:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Delivery method: nebulizer<BR/>Time administered pre-challenge: 1 hr<BR/>Mast cell agent/dose: SCG 12 mg Anticholinergic/dose: IB 120ug<BR/>Concomitant meds stopped: x 24 hrs. All received ketotifen 2.0 mg or placebo 90 min before test drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: N/R</P>
<P>Results for clemastine and ketotifen not included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>Statistical issues: Values calculated from IPD table 3<BR/>All received ketotifen 90 minutes prior to other drugs. Since it had no effect on EIB included the study.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gehrke-1986">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 2<BR/>Def'n EIB: max fall PFT =&gt;20%<BR/>Exercise challenge: treadmill x 6 min. 5 challenges over 5 different days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Recruitment: N/R<BR/>Sample size: 10; M=6, F=4.<BR/>Mean age: 19-48 yrs<BR/>Inclusion: Hx EIB, PFT &gt;65%, steroid use not reported.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: Max fall PEFR 46.1% sd 11.7%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: NR<BR/>Time administered pre-challenge: 15 min<BR/>Mast cell agent/dose: SCG 1 mg<BR/>Beta2 agonist/dose: fenoterol 0.05 mg and 0.2 mg<BR/>Combined SCG/fenoterol 1 mg/0.05 mg<BR/>Concomitant meds stopped: oral x24h, inhaled x 8 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: maximum % fall<BR/>ADRs: tremor/agitation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: results calculated from IPD, dropouts not included.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Godfrey-1975">
<CHAR_METHODS>
<P>Methods: RCT, SB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: NR but max fall PEFR=44.87% sd 15.6 on placebo. <BR/>Exercise challenge: inclined treadmill x 6 min, Hr =170-180, consistent settings, <BR/>4 challenges over 4 days in 2 separate 1 wk periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Recruitment: Volunteers, Dept. Pediatrics<BR/>Sample size: 15; M=13, F=2.<BR/>Mean age: 8.7 yr<BR/>Inclusion: Hx asthma, PFT &gt;65% predicted, steroid use not reported.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: Max fall PEFR 45.2% sd 15.49%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI, spinhaler, oral, nebuliser. <BR/>Time administered pre-challenge: 10 min inhaled, 2 hrs oral<BR/>Mast cell agent/dose: SCG 20 mg spinhaler<BR/>Beta2 agonist/dose: salbutamol 200ug MDI (13 pts) oral 3-4 mg (2 pts)<BR/> Anticholinergic agent/dose: Atropine 0.2% sol'n @ 9 L/min x 3 min IV.</P>
<P>Concomitant meds stopped: x 12 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: N/R</P>
<P>Theophylline results not included</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>Statistical issues: results estimated from IPD Table 2. Authors saw no difference between delivery methods so combined results.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-07 10:39:00 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Godfrey-1976">
<CHAR_METHODS MODIFIED="2008-08-07 10:38:50 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Same study as <LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-07 10:38:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Same study as <LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-07 10:38:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Same study as <LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-07 10:38:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Same study as <LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-07 10:39:00 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Same study as <LINK REF="STD-Godfrey-1975" TYPE="STUDY">Godfrey 1975</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neijens-1981a">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1 &gt;15%<BR/>Exercise challenge: inclined treadmill x 6 min. HR 175, consistent settings, <BR/>4 challenges in 4 consecutive days. T=22C, RH=70%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands<BR/>Recruitment: Volunteers from Outpatient clinic<BR/>Sample size: 13; M=9, F=4.<BR/>Mean age: 12.5 yrs<BR/>Inclusion: Hx asthma, PFT &gt;60% predicted, stable, reproducible EIB<BR/>Exclusion: If receiving SCG, CS, B2 agonists in past 2 wks.<BR/>Mean severity on placebo: max fall FEV1 27.5% sd 11.54%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI, nebuliser.<BR/>Time administered pre-challenge: 20 min<BR/>Mast cell agent/dose: SCG 20mg <BR/>Beta2 agonist/dose: fenoterol 0.4 mg<BR/>Anticholinergic/dose: oxytropium bromide 0.02 mg<BR/>Concomitant meds stopped: x 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall</P>
<P>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Obata-1993">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall PEFR &gt;20%<BR/>Exercise challenge: bicycle x 6 min, consistent settings, <BR/>3 challenges on 3 separate days over 10 days. T=20-24C, RH=56-67%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Recruitment: N/R<BR/>Sample size: 14; M=10, F=4.<BR/>Mean age: 12.7y sd 3.0<BR/>Inclusion: Hx asthma (ATS criteria), PFT &gt;70% predicted. None on OCS, 6/14 on ICS<BR/>Exclusion: N/R<BR/>Mean severity on placebo: Max fall PEFR 39.6% sd 16.09%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: nebulizer<BR/>Time administered pre-challenge: 1 hr<BR/>Mast cell agent/dose: SCG 20mg<BR/>Beta2 agonist/dose: procaterol 1ug/kg</P>
<P>Concomitant meds stopped: theophylline x 24 hr, others x 12 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>PEFR: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues:<BR/>Results calculated from IPD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pichaipat-1995">
<CHAR_METHODS>
<P>Methods: no blinding, X-over<BR/>Withdrawals: 3 (no EIB on test run)<BR/>Def'n EIB: Max fall FEV1=&gt;20%<BR/>Exercise challenge: bicycle x 7-8 min. HR&gt;170, consistent settings, <BR/>4 challenges over 45 days, 7 days between. T=23-25C, RH=65-75%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Thailand<BR/>Recruitment: Pediatric allergy clinic<BR/>Sample size: 11; M=8, F=3.<BR/>Mean age: 11y<BR/>Inclusion: Hx asthma &amp; EIB. None on CS, antihistamine or anticholinergics. PFT &gt;80% predicted on test day. None on OCS or ICS.<BR/>Exclusion: No heart disease, URTI, active bronchospasm or thyrotoxicosis. <BR/>Mean severity on placebo: max fall FEV1 28.23% sd 7.98%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI<BR/>Time administered pre-challenge: 15 min<BR/>Mast cell agent/dose: SCG 10 mg<BR/>Beta2 agonist/dose: terbutaline 200 ug<BR/>Concomitant meds stopped: Methylxanthine and B2 x 8 -12 hrs, SCG and CS x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: N/R</P>
<P>
<BR/>Budesonide results not included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 1<BR/>Statistical issues: results calculated from IPD<BR/> It is not known if study was randomized but is included pending contact with the author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rohr-1987">
<CHAR_METHODS>
<P>Methods: RCT, SB (evaluator), parallel group<BR/>Withdrawals: 3<BR/>Def'n EIB: Max fall FEV1=&gt;20%<BR/>Exercise challenge: inclined treadmill x 6-8 min HR 80-90% max. consistent settings, <BR/>2 challenges 1 week apart. T=25C, RH=47%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, 2 centres<BR/>Recruitment: N/R<BR/>Sample size: 80; M=46, F=37.<BR/>Mean age: 24y<BR/>Inclusion: Hx asthma (mild), Hx EIB, none on CS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: max fall FEV1 32%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: spinhaler, MDI<BR/>Time administered pre-challenge: 15 min<BR/>Mast cell agent/dose: SCG 20 mg <BR/>Beta2 agonist/dose: albuterol 180 ug<BR/>Concomitant meds: none permitted throughout the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 1<BR/>Statistical issues: sd imputed from weighted average of other studies<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Spada-1985">
<CHAR_METHODS>
<P>Methods: RCT, crossover<BR/>Withdrawals: 0<BR/>Def'n EIB: Max fall FEV1 =&gt;15%<BR/>Exercise challenge: treadmill at 80% maximum cardio function<BR/>4 challenges. T=18-22 C, RH 40-50%,</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Recruitment: ambulatory volunteers<BR/>Sample size: 100; M=65, F=35.<BR/>Mean age: 19.8y sd 10.2<BR/>Inclusion: Hx asthma (ATS criteria), reproducible EIB, at 80% of predicted PFT, steroid use not reported.<BR/>Exclusion:<BR/>Mean severity on placebo: max fall FEV1 22.82% sd 5.29%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI<BR/>Time administered pre-challenge: 15-45 min. <BR/>Mast cell agent/dose: SCG 20 mg<BR/>Beta2 agonist/dose: salbutamol 0.2 mg<BR/>Anticholinergic/dose: IB 40 ug</P>
<P>Concomitant meds stopped: x 24 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: change in % predicted<BR/>Complete protection<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Svenonius-1988">
<CHAR_METHODS>
<P>Methods: RCT, SB (patient), X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: Max fall FEV1 =&gt;20%<BR/>Exercise challenge: inclined treadmill x 6 min. HR 170. Consistent settings, <BR/>5 challenges.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Sweden<BR/>Recruitment: volunteers<BR/>Sample size: 7; M=3, F=3.<BR/>Mean age: 13.9y sd 2.9<BR/>Inclusion: Hx asthma, Reproducible EIB, only on SABA, none on CS. <BR/>Exclusion: if had infection or asthma exacerbation<BR/>Mean severity on placebo: max fall FEV1 22.82% sd 5.29%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI &amp; spacer<BR/>Time administered pre-challenge: 15 min. IB 1 hr.<BR/>Mast cell agent/dose: SCG 3 mg<BR/>Beta2 agonist/dose: salbutamol 0.3 mg<BR/>Anticholinergic/dose: IB 80 ug<BR/>Combined SCG/B2<BR/>Concomitant meds stopped: x 12 hr (only on B2 agonists)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: change in % predicted<BR/>Complete protection<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>Statistical issues: <BR/>% predicted results not included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thompson-1978">
<CHAR_METHODS>
<P>Methods: RCT, DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: N/R<BR/>Exercise challenge: inclined treadmill x 5-8 min. HR 170-180. Consistent settings. <BR/>4 challenges in 10 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Recruitment: N/R<BR/>Sample size: 13; M=7, F=6.<BR/>Mean age: (17-33y)<BR/>Inclusion: Hx asthma, all non-smokers.<BR/>Exclusion: current ICS use<BR/>Mean severity on placebo: Max fall FEV1 38%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: nebulizer<BR/>Time administered pre-challenge: 20 min<BR/>Mast cell agent/dose: SCG 20 mg<BR/>Anticholinergic/dose: IB 2.0 mg<BR/>Combined SCG/IB<BR/>Concomitant meds stopped: x 24 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>ADRs: none were seen</P>
<P>
<BR/>Combination results not included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: reviewers averaged the results from helium responder/nonresponder groups weighted by sample size.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tullett-1982">
<CHAR_METHODS>
<P>Methods: RCT, SB, X-over<BR/>Withdrawals: 4 (severe bronchoconstriction after inhaling lignocaine)<BR/>Def'n EIB: =&gt;20%<BR/>Exercise challenge: inclined treadmill x 8 min. HR 160. Consistent settings, <BR/>4 challenges in 7-10 days. T=20-22C, RH=20-40%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Recruitment: N/R<BR/>Sample size: 8; M=5, F=3.<BR/>Mean age: 31.2y sd 11.31<BR/>Inclusion: Hx asthma, reproducible EIA. All non-smokers.<BR/>Exclusion: Current OCS/ICS or antihistamine use<BR/>Mean severity on placebo: Max fall FEV1 37.28% sd12.55%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: nebulizer<BR/>Time administered pre-challenge: 30 min<BR/>Mast cell agent/dose: SCG 12 mg<BR/>Anticholinergic/dose: IB 120ug<BR/>Concomitant meds stopped: x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: both well tolerated</P>
<P>Lignocaine results not included</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>Statistical issues: results calculated from IPD<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vazquez-1984">
<CHAR_METHODS>
<P>Methods: RCT, DB, parallel<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1 =&gt;15%<BR/>Exercise challenge: stair climbing as fast as possible for 5-8 min. HR = 170<BR/> T/RH - NR</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Spain<BR/>Recruitment: volunteers from clinic<BR/>Sample size: 49; M/F NR.<BR/>Mean age: 9.4y sd 2.05<BR/>Inclusion: Hx of EIB. All except 2 were atopic. Asymptomatic asthma (ATS criteria), 80 of predicted, steroid use not reported.<BR/>Exclusion: NR<BR/>Mean severity on placebo: Max fall FEV1 14.3% sd9.8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: nebulised<BR/>Time administered pre-challenge: 15 min<BR/>Mast cell agent/dose: SCG 20 mg N=12<BR/>Beta2 agonist/dose: salbutamol 4mg N=13<BR/>Anticholinergic: IB 0.4mg N=12<BR/>Placebo: N=12<BR/>Concomitant meds stopped:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: <BR/>Complete protection</P>
<P>ADRs:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 3<BR/>Statistical issues: original paper in Spanish.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woolley-1990">
<CHAR_METHODS>
<P>Methods: RCT (Latin Square), DB, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1 =&gt;20%<BR/>Exercise challenge: inclined treadmill x 8 min. to 60% MVV consistent settings, <BR/>4 challenges separated by 2 hrs. on separate days over 3 wks. T=19-22C, RH=59-83%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia<BR/>Recruitment: volunteers<BR/>Sample size: 12; M=7, F=5.<BR/>Mean age: 20.9y sd 3.2<BR/>Inclusion: Hx of EIB needing treatment. All non-smokers. PFT &gt;60% predicted on test days and stable over test period. 1/12 on ICS<BR/>Exclusion:<BR/>Mean severity on placebo: max fall FEV1 33.75%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: MDI<BR/>Time administered pre-challenge: 10 min<BR/>Mast cell agent/dose: SCG 2.0 mg<BR/>Beta2 agonist/dose: terbutaline 0.5mg<BR/>Combination SCG/terbutaline<BR/>Concomitant meds stopped: inhaled x 8 hr, oral x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall<BR/>Complete protection<BR/>Clinical protection<BR/>ADRs: mild throat irritation on SCG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 5<BR/>Statistical issues: none<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zanconato-1990">
<CHAR_METHODS>
<P>Methods: RCT, X-over<BR/>Withdrawals: 0<BR/>Def'n EIB: max fall FEV1 =&gt;20%<BR/>Exercise challenge: inclined treadmill @6.5 k/hr until exhaustion. Performed in afternoon. 3 challenges in 15 days. <BR/> T=21-24C, RH= 50-70%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Recruitment: Allergy centre in pediatric department <BR/>Sample size: 12; M=8, F=4.<BR/>Mean age: 10.7y sd 2.8<BR/>Inclusion: all had mild to moderate atopic asthma. 3/12 on ICS.<BR/>Exclusion: N/R<BR/>Mean severity on placebo: max fall FEV1 32.8% sd 11.6%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Delivery method: Spinhaler and MDI<BR/>Time administered pre-challenge: 30 min.<BR/>Mast cell agent/dose: SCG 40 mg (spinhaler)<BR/>Beta2 agonist/dose: Albuterol 200ug MDI</P>
<P>Concomitant meds stopped: x 24 hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reported outcomes:<BR/>FEV1: maximum % fall</P>
<P>
<BR/>ADRs: N/R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score: 2<BR/>Statistical issues: none<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADR=adverse reaction</P>
<P>B2=beta 2 agonist</P>
<P>BD=bronchodilators</P>
<P>BL=baseline</P>
<P>CS=corticosteroids OCS=oral corticosteroids ICS=inhaled corticosteroids</P>
<P>CV=cardiovascular disease</P>
<P>DB=double blind SB=single blind</P>
<P>Def'n=definition of EIB used</P>
<P>EIB=exercise-induced bronchospasm</P>
<P>F=female</P>
<P>FEV1=forced expiratory volume in one second</P>
<P>HR=heart rate</P>
<P>Hx=history of</P>
<P>IB=ipratropium bromide</P>
<P>IPD= Individual patient data</P>
<P>M=male</P>
<P>MDI=metered dose inhaler</P>
<P>neb=nebulizer</P>
<P>NR=not reported</P>
<P>PEFR=peak expiratory flow rate</P>
<P>PFT = pulmonary function test</P>
<P>RCT=randomised controlled trial</P>
<P>RH=relative humidity</P>
<P>SCG=sodium cromoglycate</P>
<P>SDs=standard deviations</P>
<P>URTI=upper respiratory tract infection</P>
<P>Complete protection = &lt;15% fall in PFT post exercise</P>
<P/>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bauer-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>No included outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bauer-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No included outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boner-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (author communication)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bundgaard-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not right interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ceugniet-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not right interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cummings-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized, drugs given sequentially</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Cree-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not right interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eggleston-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gimeno-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guerin-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not right interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No included outcome measures<BR/>Reported change from 0, no baseline values reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joppich-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neijens-1981b">
<CHAR_REASON_FOR_EXCLUSION>
<P>CARA is not asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rachelefsky-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No included outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rasmussen-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only reported the Jones liability index</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ringel-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not right interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spada-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tabas-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Beta agonists were given orally. Not stated if randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tashkin-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No included outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Verini-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woolley-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>None identified.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-07 10:40:00 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-07 10:40:00 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:36:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1987">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:36:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1889">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:36:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bundgaard-1980">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:36:46 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bundgaard-1983a">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:36:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bundgaard-1983p">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:37:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Bundgaard-1986neb">
<DESCRIPTION>
<P>4x4 William's Square, DB, X-over, conducted 2 studies same protocol, different participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:37:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Bundgaard-1986pdr">
<DESCRIPTION>
<P>4x4 William's Square, DB, X-over, conducted 2 studies same protocol, different participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:37:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Clarke-1990">
<DESCRIPTION>
<P>Latin Square, DB, double dummy, X-over. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Dorward-1982">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gehrke-1986">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Godfrey-1975">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:37 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Godfrey-1976">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Neijens-1981a">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Obata-1993">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pichaipat-1995">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rohr-1987">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Spada-1985">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Svenonius-1988">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1978">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:31 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Tullett-1982">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Vazquez-1984">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:39:52 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Woolley-1990">
<DESCRIPTION>
<P>Third party, concealed randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:40:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Zanconato-1990">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-07 10:38:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-de-Benedictis-1998">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>MCS vs anticholinergics (AC)</NAME>
<CONT_OUTCOME CHI2="1.8723392247908943" CI_END="-3.3108628341854485" CI_START="-10.040915391689179" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.6758891129373135" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.9665668822144653" P_Q="0.959066056752598" P_Z="1.0091537695588001E-4" Q="0.0026343212488468826" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="100.0" Z="3.8883803995115924">
<NAME>Maximum percent decrease in PFT</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.11634958566781017" CI_END="-0.9476679949919387" CI_START="-12.168974436873215" DF="3.0" EFFECT_SIZE="-6.558321215932577" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.9898056971963594" P_Z="0.021962724524110976" STUDIES="4" TAU2="0.0" TOTAL_1="55" TOTAL_2="47" WEIGHT="35.970797479272086" Z="2.2910119153858117">
<NAME>Children</NAME>
<CONT_DATA CI_END="4.503172707978136" CI_START="-16.96317270797814" EFFECT_SIZE="-6.23" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="21.73" ORDER="4" SD_1="11.67" SD_2="17.71" SE="5.476209151106874" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.829256875009621"/>
<CONT_DATA CI_END="13.590234390086607" CI_START="-24.07023439008661" EFFECT_SIZE="-5.240000000000002" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="24.57" ORDER="5" SD_1="18.28" SD_2="22.14" SE="9.60743898286759" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" WEIGHT="3.19348932223357"/>
<CONT_DATA CI_END="4.291104751621098" CI_START="-15.891104751621096" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="12.5" ORDER="6" SD_1="7.57" SD_2="16.95" SE="5.1486174395134015" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="11.11986440262758"/>
<CONT_DATA CI_END="1.884291237866008" CI_START="-17.684291237866006" EFFECT_SIZE="-7.8999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="12.1" ORDER="7" SD_1="6.8" SD_2="15.9" SE="4.992077056029217" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.828186879401313"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7533553178742372" CI_END="-2.5366137373338615" CI_START="-10.947260808555129" DF="3.0" EFFECT_SIZE="-6.741937272944495" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.6251376658805452" P_Z="0.0016768527406808976" STUDIES="4" TAU2="0.0" TOTAL_1="128" TOTAL_2="128" WEIGHT="64.0292025207279" Z="3.142196820079069">
<NAME>Adults</NAME>
<CONT_DATA CI_END="2.3890670936047798" CI_START="-31.80906709360478" EFFECT_SIZE="-14.71" ESTIMABLE="YES" MEAN_1="8.86" MEAN_2="23.57" ORDER="8" SD_1="11.88" SD_2="19.79" SE="8.72417413201469" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="3.8728625817287328"/>
<CONT_DATA CI_END="-0.7932891285917592" CI_START="-10.086710871408242" EFFECT_SIZE="-5.44" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="9.88" ORDER="9" SD_1="16.2" SD_2="17.31" SE="2.37081441703057" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="52.442769556841185"/>
<CONT_DATA CI_END="3.8591735284872115" CI_START="-27.479173528487213" EFFECT_SIZE="-11.81" ESTIMABLE="YES" MEAN_1="14.58" MEAN_2="26.39" ORDER="10" SD_1="21.08" SD_2="19.66" SE="7.994623193121737" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.6119515889645495"/>
<CONT_DATA CI_END="7.837076851644804" CI_START="-30.37707685164481" EFFECT_SIZE="-11.270000000000001" ESTIMABLE="YES" MEAN_1="11.17" MEAN_2="22.44" ORDER="11" SD_1="11.48" SD_2="25.07" SE="9.748687732202729" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.1016187931934365"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.5258034289674" CI_END="3.680551078179163" CI_START="1.2572655794498466" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.1511462488640056" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="94" I2="6.986675029851855" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5659128491882748" LOG_CI_START="0.09942702590137857" LOG_EFFECT_SIZE="0.33266993754482665" METHOD="MH" NO="2" P_CHI2="0.37625623375056005" P_Q="0.0" P_Z="0.0051826006478633176" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04841017862170925" TOTALS="YES" TOTAL_1="177" TOTAL_2="169" WEIGHT="99.99999999999997" Z="2.7954594278250813">
<NAME>Complete protection: post exercise fall PFT &lt;15% (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors MCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.613176742518052" CI_END="6.157105940590915" CI_START="0.39077837813192684" DF="3.0" EFFECT_SIZE="1.5511492105695601" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" I2="46.554328544905026" ID="CMP-001.02.01" LOG_CI_END="0.7893766262272162" LOG_CI_START="-0.40806947391378273" LOG_EFFECT_SIZE="0.19065357615671674" NO="1" P_CHI2="0.1320240625923068" P_Z="0.5325497568392942" STUDIES="4" TAU2="0.9033864962449586" TOTAL_1="49" TOTAL_2="41" WEIGHT="29.70629508613463" Z="0.6241185181477966">
<NAME>Children</NAME>
<DICH_DATA CI_END="7.291907385170156" CI_START="0.4030187651835494" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.8628411440250432" LOG_CI_START="-0.3946747319583073" LOG_EFFECT_SIZE="0.23408320603336794" ORDER="12" O_E="0.0" SE="0.7386710503565986" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.5456349206349207" WEIGHT="12.639581261849285"/>
<DICH_DATA CI_END="7.11647949720811" CI_START="0.191261860818273" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8522652024776365" LOG_CI_START="-0.71837162321641" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="13" O_E="0.0" SE="0.9225998461903602" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" VAR="0.8511904761904762" WEIGHT="8.346460471202176"/>
<DICH_DATA CI_END="2.7631151946828556" CI_START="0.03257193191698618" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4413989910953924" LOG_CI_START="-1.4871564816560676" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="14" O_E="0.0" SE="1.1328430311977618" STUDY_ID="STD-Svenonius-1988" TOTAL_1="7" TOTAL_2="7" VAR="1.2833333333333332" WEIGHT="5.6380836383687765"/>
<DICH_DATA CI_END="516.6901747383918" CI_START="1.209622382148929" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="2.7132302031801303" LOG_CI_START="0.08264981416394487" LOG_EFFECT_SIZE="1.3979400086720377" ORDER="15" O_E="0.0" SE="1.5452159420910423" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="12" VAR="2.3876923076923076" WEIGHT="3.0821697147143943"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0813193974652668" CI_END="4.438400032910393" CI_START="1.4596477906938095" DF="3.0" EFFECT_SIZE="2.5452899249894867" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="74" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.6472264426134509" LOG_CI_START="0.1642480742697742" LOG_EFFECT_SIZE="0.40573725844161257" NO="2" P_CHI2="0.7815854891202508" P_Z="9.911494135983248E-4" STUDIES="4" TAU2="0.0" TOTAL_1="128" TOTAL_2="128" WEIGHT="70.29370491386534" Z="3.293027041599148">
<NAME>Adults</NAME>
<DICH_DATA CI_END="106.93596341493117" CI_START="0.5984890204960159" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="2.029123786462397" LOG_CI_START="-0.2229438124785104" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="16" O_E="0.0" SE="1.3228756555322954" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" VAR="1.75" WEIGHT="4.175066063634023"/>
<DICH_DATA CI_END="4.967149714727494" CI_START="1.374483085779973" EFFECT_SIZE="2.6129032258064515" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="62" LOG_CI_END="0.6961072502509337" LOG_CI_START="0.13813939983782034" LOG_EFFECT_SIZE="0.41712332504437705" ORDER="17" O_E="0.0" SE="0.327753077318067" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" VAR="0.10742207969146282" WEIGHT="48.18310012659829"/>
<DICH_DATA CI_END="8.894231096232069" CI_START="0.3917645501611247" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.9491084094073281" LOG_CI_START="-0.40697486483425227" LOG_EFFECT_SIZE="0.27106677228653797" ORDER="18" O_E="0.0" SE="0.7965700280099732" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" VAR="0.6345238095238095" WEIGHT="10.9944466604254"/>
<DICH_DATA CI_END="12.221392528015418" CI_START="0.22728815651818765" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="1.08712069304054" LOG_CI_START="-0.6434231938078273" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="19" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" VAR="1.0333333333333332" WEIGHT="6.941092063207635"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6624728108380262" CI_END="6.410080850285513" CI_START="1.13911606433339" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.702189125549147" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.8068635073053102" LOG_CI_START="0.05656797652116845" LOG_EFFECT_SIZE="0.4317157419132393" METHOD="MH" NO="3" P_CHI2="0.797522676932378" P_Q="0.0" P_Z="0.02410170810207317" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="48" WEIGHT="100.0" Z="2.2555040540481985">
<NAME>Clinical Protection: 50% improvement over placebo (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors MCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8674585568532894" CI_END="11.864164502492242" CI_START="0.9228646366942062" DF="1.0" EFFECT_SIZE="3.30893001788687" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.074237159769259" LOG_CI_START="-0.03486199545073654" LOG_EFFECT_SIZE="0.5196875821592613" NO="1" P_CHI2="0.35165994216864704" P_Z="0.0662468082514327" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="22" WEIGHT="45.76399927757234" Z="1.8367500136501573">
<NAME>Children</NAME>
<DICH_DATA CI_END="10.510529570116088" CI_START="0.3805707384500341" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="1.0216245983864845" LOG_CI_START="-0.4195646070585221" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="20" O_E="0.0" SE="0.8465616732800195" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.7166666666666666" WEIGHT="27.10333405490707"/>
<DICH_DATA CI_END="50.782101790090834" CI_START="0.9307536185755706" EFFECT_SIZE="6.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.7057106716646968" LOG_CI_START="-0.03116526666009629" LOG_EFFECT_SIZE="0.8372727025023002" ORDER="21" O_E="0.0" SE="1.0202495238465397" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" VAR="1.040909090909091" WEIGHT="18.66066522266527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6169473241412916" CI_END="7.360124754858954" CI_START="0.7048328345104088" DF="2.0" EFFECT_SIZE="2.2776429907510667" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.8668851757352775" LOG_CI_START="-0.15191387259468164" LOG_EFFECT_SIZE="0.3574856515702979" NO="2" P_CHI2="0.7345673392096629" P_Z="0.16898867625023056" STUDIES="3" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.23600072242766" Z="1.3754606528464204">
<NAME>Adults</NAME>
<DICH_DATA CI_END="7.714147613560493" CI_START="0.2688048121291942" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.8872879450228164" LOG_CI_START="-0.5705629608323171" LOG_EFFECT_SIZE="0.15836249209524964" ORDER="22" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Boulet-1889" TOTAL_1="11" TOTAL_2="11" VAR="0.7333333333333333" WEIGHT="26.487349190022815"/>
<DICH_DATA CI_END="60.1514794208988" CI_START="0.33665007402900904" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="1.7792463132457974" LOG_CI_START="-0.47282128569511017" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="23" O_E="0.0" SE="1.3228756555322954" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" VAR="1.75" WEIGHT="11.09946061296194"/>
<DICH_DATA CI_END="24.91862084290608" CI_START="0.36117568691856994" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="1.3965240019963445" LOG_CI_START="-0.44228149255701976" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" VAR="1.1666666666666665" WEIGHT="16.649190919442912"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.268945550221218" CI_END="20.0155268456917" CI_START="2.3994652670918875" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.207496056391793" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.5113793383728679" P_Q="0.790229695357932" P_Z="0.012635053343466113" Q="0.07076257573583611" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="2.493893260919058">
<NAME>Mean degree of clinical protection: PFT comparison</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6456375243014094" CI_END="20.212279404978865" CI_START="1.2504799550075223" DF="2.0" EFFECT_SIZE="10.731379679993195" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.7241051324105194" P_Z="0.026522615642499487" STUDIES="3" TAU2="0.0" TOTAL_1="43" TOTAL_2="35" WEIGHT="86.30948825854807" Z="2.2184727491402105">
<NAME>Children</NAME>
<CONT_DATA CI_END="30.48686503690184" CI_START="-6.046865036901842" EFFECT_SIZE="12.219999999999999" ESTIMABLE="YES" MEAN_1="65.28" MEAN_2="53.06" ORDER="25" SD_1="21.56" SD_2="28.95" SE="9.320000357653784" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="23.25035605725265"/>
<CONT_DATA CI_END="81.23515884219083" CI_START="-21.055158842190835" EFFECT_SIZE="30.089999999999996" ESTIMABLE="YES" MEAN_1="60.05" MEAN_2="29.96" ORDER="26" SD_1="40.18" SD_2="63.35" SE="26.094948297834712" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" WEIGHT="2.9658459175131013"/>
<CONT_DATA CI_END="20.562289402611395" CI_START="-2.162289402611396" EFFECT_SIZE="9.2" ESTIMABLE="YES" MEAN_1="25.8" MEAN_2="16.6" ORDER="27" SD_1="14.78" SD_2="14.78" SE="5.7971929546847205" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="60.09328628378233"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.552545450183973" CI_END="45.7878166073673" CI_START="-17.695067440333645" DF="2.0" EFFECT_SIZE="14.046374583516826" ESTIMABLE="YES" I2="43.70233884280277" ID="CMP-001.04.02" NO="2" P_CHI2="0.1692679353518184" P_Z="0.3857597938086794" STUDIES="3" TAU2="343.88806228722524" TOTAL_1="26" TOTAL_2="26" WEIGHT="13.690511741451932" Z="0.8673326270547347">
<NAME>Adults</NAME>
<CONT_DATA CI_END="23.386467553001893" CI_START="-60.40646755300189" EFFECT_SIZE="-18.509999999999998" ESTIMABLE="YES" MEAN_1="35.15" MEAN_2="53.66" ORDER="28" SD_1="55.36" SD_2="44.29" SE="21.37614154314869" STUDY_ID="STD-Boulet-1889" TOTAL_1="11" TOTAL_2="11" WEIGHT="4.4198021935727505"/>
<CONT_DATA CI_END="76.43041516675541" CI_START="-7.390415166755417" EFFECT_SIZE="34.519999999999996" ESTIMABLE="YES" MEAN_1="77.27" MEAN_2="42.75" ORDER="29" SD_1="28.14" SD_2="49.08" SE="21.383257803377724" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="4.416860899104489"/>
<CONT_DATA CI_END="65.49934816716595" CI_START="-14.459348167165956" EFFECT_SIZE="25.519999999999996" ESTIMABLE="YES" MEAN_1="71.19" MEAN_2="45.67" ORDER="30" SD_1="31.54" SD_2="48.31" SE="20.398001433964065" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.853848648774691"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>ADRS</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>IB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>General side effects</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.0" STUDY_ID="STD-Bundgaard-1980" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="0.0" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.8723392247908943" CI_END="-3.3108628341854467" CI_START="-10.040915391689177" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.675889112937312" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.9665668822144653" P_Q="0.7723247719918691" P_Z="1.009153769558803E-4" Q="0.08371494687227088" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="99.99999999999999" Z="3.8883803995115915">
<NAME>High vs low quality</NAME>
<GROUP_LABEL_1>MSC</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.332924556449007" CI_END="-2.039320095051247" CI_START="-10.544706262602013" DF="3.0" EFFECT_SIZE="-6.29201317882663" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.7213302040057813" P_Z="0.003733560676187945" STUDIES="4" TAU2="0.0" TOTAL_1="130" TOTAL_2="122" WEIGHT="62.61074025399692" Z="2.8998375800502343">
<NAME>Low quality (Jadad 1-2)</NAME>
<CONT_DATA CI_END="2.3890670936047798" CI_START="-31.80906709360478" EFFECT_SIZE="-14.71" ESTIMABLE="YES" MEAN_1="8.86" MEAN_2="23.57" ORDER="35" SD_1="11.88" SD_2="19.79" SE="8.72417413201469" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="3.8728625817287328"/>
<CONT_DATA CI_END="13.590234390086607" CI_START="-24.07023439008661" EFFECT_SIZE="-5.240000000000002" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="24.57" ORDER="36" SD_1="18.28" SD_2="22.14" SE="9.60743898286759" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" WEIGHT="3.19348932223357"/>
<CONT_DATA CI_END="-0.7932891285917592" CI_START="-10.086710871408242" EFFECT_SIZE="-5.44" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="9.88" ORDER="37" SD_1="16.2" SD_2="17.31" SE="2.37081441703057" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="52.442769556841185"/>
<CONT_DATA CI_END="7.837076851644804" CI_START="-30.37707685164481" EFFECT_SIZE="-11.270000000000001" ESTIMABLE="YES" MEAN_1="11.17" MEAN_2="22.44" ORDER="38" SD_1="11.48" SD_2="25.07" SE="9.748687732202729" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.1016187931934365"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4556997214696164" CI_END="-1.8155176778520632" CI_START="-12.821910842446151" DF="3.0" EFFECT_SIZE="-7.318714260149107" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.92851047108171" P_Z="0.009145659144092804" STUDIES="4" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="37.38925974600306" Z="2.606560777635273">
<NAME>High quality ( Jadad 3-5)</NAME>
<CONT_DATA CI_END="4.503172707978136" CI_START="-16.96317270797814" EFFECT_SIZE="-6.23" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="21.73" ORDER="39" SD_1="11.67" SD_2="17.71" SE="5.476209151106874" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.829256875009621"/>
<CONT_DATA CI_END="4.291104751621098" CI_START="-15.891104751621096" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="12.5" ORDER="40" SD_1="7.57" SD_2="16.95" SE="5.1486174395134015" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="11.11986440262758"/>
<CONT_DATA CI_END="3.8591735284872115" CI_START="-27.479173528487213" EFFECT_SIZE="-11.81" ESTIMABLE="YES" MEAN_1="14.58" MEAN_2="26.39" ORDER="41" SD_1="21.08" SD_2="19.66" SE="7.994623193121737" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.6119515889645495"/>
<CONT_DATA CI_END="1.884291237866008" CI_START="-17.684291237866006" EFFECT_SIZE="-7.8999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="12.1" ORDER="42" SD_1="6.8" SD_2="15.9" SE="4.992077056029217" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.828186879401313"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8723392247908943" CI_END="-3.3108628341854494" CI_START="-10.040915391689179" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.675889112937314" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.9665668822144653" P_Q="0.41659469921199266" P_Z="1.0091537695587963E-4" Q="0.6599024012680379" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="100.0" Z="3.8883803995115933">
<NAME>Effect by severity</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1984194314475856" CI_END="-2.0035387693625863" CI_START="-9.75456523693329" DF="2.0" EFFECT_SIZE="-5.8790520031479385" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.9055528531962564" P_Z="0.0029469890845258335" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="125" WEIGHT="75.39082083887008" Z="2.973213996266853">
<NAME>Mild EIB (&lt; 30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="4.291104751621098" CI_START="-15.891104751621096" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="12.5" ORDER="43" SD_1="7.57" SD_2="16.95" SE="5.1486174395134015" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="11.11986440262758"/>
<CONT_DATA CI_END="-0.7932891285917592" CI_START="-10.086710871408242" EFFECT_SIZE="-5.44" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="9.88" ORDER="44" SD_1="16.2" SD_2="17.31" SE="2.37081441703057" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="52.442769556841185"/>
<CONT_DATA CI_END="1.884291237866008" CI_START="-17.684291237866006" EFFECT_SIZE="-7.8999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="12.1" ORDER="45" SD_1="6.8" SD_2="15.9" SE="4.992077056029217" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.828186879401313"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0140173920752709" CI_END="-2.333736669772832" CI_START="-15.900301414389212" DF="4.0" EFFECT_SIZE="-9.117019042081022" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.9076631677269449" P_Z="0.008431724705929719" STUDIES="5" TAU2="0.0" TOTAL_1="58" TOTAL_2="50" WEIGHT="24.60917916112991" Z="2.634274675309479">
<NAME>Severe EIB (=&gt;30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="4.503172707978136" CI_START="-16.96317270797814" EFFECT_SIZE="-6.23" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="21.73" ORDER="46" SD_1="11.67" SD_2="17.71" SE="5.476209151106874" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.829256875009621"/>
<CONT_DATA CI_END="2.3890670936047798" CI_START="-31.80906709360478" EFFECT_SIZE="-14.71" ESTIMABLE="YES" MEAN_1="8.86" MEAN_2="23.57" ORDER="47" SD_1="11.88" SD_2="19.79" SE="8.72417413201469" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="3.8728625817287328"/>
<CONT_DATA CI_END="13.590234390086607" CI_START="-24.07023439008661" EFFECT_SIZE="-5.240000000000002" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="24.57" ORDER="48" SD_1="18.28" SD_2="22.14" SE="9.60743898286759" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="7" WEIGHT="3.19348932223357"/>
<CONT_DATA CI_END="3.8591735284872115" CI_START="-27.479173528487213" EFFECT_SIZE="-11.81" ESTIMABLE="YES" MEAN_1="14.58" MEAN_2="26.39" ORDER="49" SD_1="21.08" SD_2="19.66" SE="7.994623193121737" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.6119515889645495"/>
<CONT_DATA CI_END="7.837076851644804" CI_START="-30.37707685164481" EFFECT_SIZE="-11.270000000000001" ESTIMABLE="YES" MEAN_1="11.17" MEAN_2="22.44" ORDER="50" SD_1="11.48" SD_2="25.07" SE="9.748687732202729" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.1016187931934365"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2036270936032598" CI_END="-2.4644660159477105" CI_START="-14.263307083515251" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.36388654973148" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.8775010967857668" P_Q="1.0" P_Z="0.005457130645053232" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="2.7787333203958915">
<NAME>Effect by steroid use</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2036270936032598" CI_END="-2.4644660159477105" CI_START="-14.263307083515251" DF="4.0" EFFECT_SIZE="-8.36388654973148" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.8775010967857668" P_Z="0.005457130645053232" STUDIES="5" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.0" Z="2.7787333203958915">
<NAME>No recent steroid use</NAME>
<CONT_DATA CI_END="4.503172707978136" CI_START="-16.96317270797814" EFFECT_SIZE="-6.23" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="21.73" ORDER="51" SD_1="11.67" SD_2="17.71" SE="5.476209151106874" STUDY_ID="STD-Boner-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.21081737856153"/>
<CONT_DATA CI_END="2.3890670936047798" CI_START="-31.80906709360478" EFFECT_SIZE="-14.71" ESTIMABLE="YES" MEAN_1="8.86" MEAN_2="23.57" ORDER="52" SD_1="11.88" SD_2="19.79" SE="8.72417413201469" STUDY_ID="STD-Dorward-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="11.903478124205247"/>
<CONT_DATA CI_END="4.291104751621098" CI_START="-15.891104751621096" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="12.5" ORDER="53" SD_1="7.57" SD_2="16.95" SE="5.1486174395134015" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="34.177577920082605"/>
<CONT_DATA CI_END="3.8591735284872115" CI_START="-27.479173528487213" EFFECT_SIZE="-11.81" ESTIMABLE="YES" MEAN_1="14.58" MEAN_2="26.39" ORDER="54" SD_1="21.08" SD_2="19.66" SE="7.994623193121737" STUDY_ID="STD-Thompson-1978" TOTAL_1="13" TOTAL_2="13" WEIGHT="14.175113030896172"/>
<CONT_DATA CI_END="7.837076851644804" CI_START="-30.37707685164481" EFFECT_SIZE="-11.270000000000001" ESTIMABLE="YES" MEAN_1="11.17" MEAN_2="22.44" ORDER="55" SD_1="11.48" SD_2="25.07" SE="9.748687732202729" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="9.53301354625444"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Some on ICS (no studies)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>MCS vs short acting beta-agonist (SABA)</NAME>
<CONT_OUTCOME CHI2="13.747145483553565" CI_END="9.219293924917313" CI_START="4.46718991945013" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.843241922183721" ESTIMABLE="YES" I2="19.98338845573519" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.2473022204869425" P_Q="0.6348130925160886" P_Z="1.6530488108633954E-8" Q="0.22559021474231855" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.2565148216593243" TOTALS="YES" TOTAL_1="271" TOTAL_2="272" UNITS="" WEIGHT="100.0" Z="5.644871277877744">
<NAME>Maximum percent decrease in PFT</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.934064085580664" CI_END="10.72561373269065" CI_START="3.875130229547583" DF="6.0" EFFECT_SIZE="7.300371981119117" ESTIMABLE="YES" I2="32.84131451794892" ID="CMP-002.01.01" NO="1" P_CHI2="0.17732041955550726" P_Z="2.9491272212021996E-5" STUDIES="7" TAU2="6.476772077508283" TOTAL_1="91" TOTAL_2="92" WEIGHT="61.43256659755572" Z="4.17735949591702">
<NAME>Children</NAME>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="56" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.6489258232681094"/>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="57" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.404389352980403"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="58" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.234361652889072"/>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="59" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.093071762174185"/>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="60" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="20.760582412033987"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="61" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="13.243078814683194"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="62" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="12.048156779526774"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.587491183230583" CI_END="10.118348412284877" CI_START="2.665861741882743" DF="4.0" EFFECT_SIZE="6.39210507708381" ESTIMABLE="YES" I2="12.806371931092459" ID="CMP-002.01.02" NO="2" P_CHI2="0.33229912432281217" P_Z="7.733007921733855E-4" STUDIES="5" TAU2="2.711739621461879" TOTAL_1="180" TOTAL_2="180" WEIGHT="38.56743340244428" Z="3.362178636625155">
<NAME>Adults</NAME>
<CONT_DATA CI_END="21.017481953246005" CI_START="0.5625180467539916" EFFECT_SIZE="10.79" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.62" ORDER="63" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.820739010405447"/>
<CONT_DATA CI_END="29.51854447901122" CI_START="1.2814555209887821" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="6.9" ORDER="64" SD_1="17.4" SD_2="10.6" SE="7.203471385380801" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.665002556766301"/>
<CONT_DATA CI_END="15.20085073119181" CI_START="0.7991492688081907" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="6.0" ORDER="65" SD_1="15.49" SD_2="17.32" SE="3.6739709443597945" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.771668790861373"/>
<CONT_DATA CI_END="7.332848178162973" CI_START="-0.4528481781629723" EFFECT_SIZE="3.4400000000000004" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="1.0" ORDER="66" SD_1="17.55" SD_2="9.3" SE="1.9861835262633714" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="20.40780824890787"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="67" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="1.9022147955032904"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.821233275416523" CI_END="0.5203828701685295" CI_START="0.18410626199798397" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3095250313537019" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="192" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.2836770078708784" LOG_CI_START="-0.7349314396061449" LOG_EFFECT_SIZE="-0.5093042237385117" METHOD="MH" NO="2" P_CHI2="0.5607716151605754" P_Q="0.0" P_Z="9.68042736207641E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="225" TOTAL_2="226" WEIGHT="100.0" Z="4.424191167998226">
<NAME>Complete protection: post exercise fall PFT &lt;15% (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors MCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.383607538715736" CI_END="0.4583691426687124" CI_START="0.07433792096024325" DF="4.0" EFFECT_SIZE="0.1845920071355236" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="63" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.33878462668590315" LOG_CI_START="-1.1287895891660396" LOG_EFFECT_SIZE="-0.7337871079259715" NO="1" P_CHI2="0.6655917141841144" P_Z="2.716017835508309E-4" STUDIES="6" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="32.627464176418194" Z="3.6409804296409622">
<NAME>Children</NAME>
<DICH_DATA CI_END="1.442011025770504" CI_START="0.062412837621619886" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.15896858105815515" LOG_CI_START="-1.2047260716188304" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="68" O_E="0.0" SE="0.801040989379861" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.6416666666666666" WEIGHT="10.94986299035657"/>
<DICH_DATA CI_END="0.6038852046767476" CI_START="0.006468530723634752" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.21904561057376504" LOG_CI_START="-2.1891943547380843" LOG_EFFECT_SIZE="-1.2041199826559248" ORDER="69" O_E="0.0" SE="1.1572751247156894" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" VAR="1.3392857142857144" WEIGHT="5.246201023824169"/>
<DICH_DATA CI_END="1.442011025770504" CI_START="0.062412837621619886" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.15896858105815515" LOG_CI_START="-1.2047260716188304" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="70" O_E="0.0" SE="0.801040989379861" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" VAR="0.6416666666666666" WEIGHT="10.94986299035657"/>
<DICH_DATA CI_END="2.327459619562942" CI_START="0.004790313491611806" EFFECT_SIZE="0.10559006211180125" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.36688215489371534" LOG_CI_START="-2.319636064200867" LOG_EFFECT_SIZE="-0.9763769546535758" ORDER="71" O_E="0.0" SE="1.5780741003758174" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" VAR="2.4903178662769454" WEIGHT="2.821391670768115"/>
<DICH_DATA CI_END="1.2535326727564806" CI_START="0.00214483004623582" EFFECT_SIZE="0.05185185185185185" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.09813565812903692" LOG_CI_START="-2.668607115090535" LOG_EFFECT_SIZE="-1.2852357284807492" ORDER="72" O_E="0.0" SE="1.625198400586784" STUDY_ID="STD-Svenonius-1988" TOTAL_1="7" TOTAL_2="7" VAR="2.641269841269841" WEIGHT="2.6601455011127664"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5867225729488577" CI_END="0.7486756122310356" CI_START="0.21111785164021263" DF="2.0" EFFECT_SIZE="0.39756607857013804" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="129" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.12570631358759016" LOG_CI_START="-0.6754750421966277" LOG_EFFECT_SIZE="-0.40059067789210884" NO="2" P_CHI2="0.4523220223414506" P_Z="0.0042865369606030195" STUDIES="3" TAU2="0.0" TOTAL_1="152" TOTAL_2="152" WEIGHT="67.37253582358181" Z="2.856267591638032">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.6991755987705217" CI_START="0.06090028747545384" EFFECT_SIZE="0.20634920634920634" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" LOG_CI_END="-0.155413736987262" LOG_CI_START="-1.2153806573062278" LOG_EFFECT_SIZE="-0.685397197146745" ORDER="74" O_E="0.0" SE="0.6226298159162375" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" VAR="0.3876678876678877" WEIGHT="18.12417873388074"/>
<DICH_DATA CI_END="1.1741142285265147" CI_START="0.2364600852306931" EFFECT_SIZE="0.5269071555292726" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="89" LOG_CI_END="0.06971035109001486" LOG_CI_START="-0.6262421582117487" LOG_EFFECT_SIZE="-0.27826590356086695" ORDER="75" O_E="0.0" SE="0.40880594898433753" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" VAR="0.16712230392498478" WEIGHT="42.042037002030504"/>
<DICH_DATA CI_END="2.770474585988176" CI_START="0.0577518381901818" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4425541706606146" LOG_CI_START="-1.2384341880046896" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="76" O_E="0.0" SE="0.9874208829065749" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.975" WEIGHT="7.206320087670563"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3081133818398882" CI_END="0.7651868126097761" CI_START="0.1753429683465189" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.36629240650416117" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.11623252330255233" LOG_CI_START="-0.7561116456338446" LOG_EFFECT_SIZE="-0.43617208446819844" METHOD="MH" NO="3" P_CHI2="0.8050746335672184" P_Q="0.0" P_Z="0.007539849293739759" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="77" WEIGHT="100.00000000000001" Z="2.6720095930144234">
<NAME>Clinical Protection: 50% improvement over placebo (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors MCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2504823398329608" CI_END="0.8820455330031802" CI_START="0.13821810134507026" DF="3.0" EFFECT_SIZE="0.349162797089839" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.054508995115787155" LOG_CI_START="-0.8594350770812914" LOG_EFFECT_SIZE="-0.4569720360985393" NO="1" P_CHI2="0.5220735928475806" P_Z="0.02605315079279703" STUDIES="4" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="63.1951691789598" Z="2.2254185887679023">
<NAME>Children</NAME>
<DICH_DATA CI_END="3.392568258401618" CI_START="0.16173494627095736" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.5305285944154721" LOG_CI_START="-0.7911961314054845" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="77" O_E="0.0" SE="0.776387646590141" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.6027777777777777" WEIGHT="23.43763852111748"/>
<DICH_DATA CI_END="1.6887012671862487" CI_START="0.004024337876680742" EFFECT_SIZE="0.08243727598566308" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.22755282927066162" LOG_CI_START="-2.395305563782671" LOG_EFFECT_SIZE="-1.0838763672560048" ORDER="78" O_E="0.0" SE="1.540680003437966" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" VAR="2.3736948729936107" WEIGHT="5.951770728771366"/>
<DICH_DATA CI_END="1.0739979960323573" CI_START="0.03895616484366894" EFFECT_SIZE="0.20454545454545456" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.0310034710163291" LOG_CI_START="-1.4094238051100543" LOG_EFFECT_SIZE="-0.6892101670468626" ORDER="79" O_E="0.0" SE="0.8461141122266492" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" VAR="0.7159090909090908" WEIGHT="19.73391292765694"/>
<DICH_DATA CI_END="2.771496266606497" CI_START="0.05456784110570379" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.44271429790474226" LOG_CI_START="-1.2630632280828407" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="80" O_E="0.0" SE="1.0019821625000387" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" VAR="1.003968253968254" WEIGHT="14.071847001414014"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03461954285291767" CI_END="1.3394061468391727" CI_START="0.1180788236849361" DF="1.0" EFFECT_SIZE="0.3976876943722829" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.1269122876808" LOG_CI_START="-0.9278279819919507" LOG_EFFECT_SIZE="-0.4004578471555753" NO="2" P_CHI2="0.8523951979973801" P_Z="0.13667280162412987" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="36.80483082104021" Z="1.4882961811914044">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.669037710308907" CI_START="0.07587004080828938" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.4263547098921807" LOG_CI_START="-1.1199296823414933" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="81" O_E="0.0" SE="0.9082951062292475" STUDY_ID="STD-Boulet-1889" TOTAL_1="11" TOTAL_2="11" VAR="0.825" WEIGHT="17.124469895900653"/>
<DICH_DATA CI_END="1.879467514294643" CI_START="0.06786550947970635" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2740348235403847" LOG_CI_START="-1.1683508862248233" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="82" O_E="0.0" SE="0.8472645058404977" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.7178571428571427" WEIGHT="19.680360925139556"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.886997513277034" CI_END="-11.923054326086476" CI_START="-33.41511841706753" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-22.669086371577002" ESTIMABLE="YES" I2="49.524680279453456" I2_Q="34.595223966773965" ID="CMP-002.04" NO="4" P_CHI2="0.06453783982182126" P_Q="0.2162719842458527" P_Z="3.555663778365432E-5" Q="1.528940332265634" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="90.89442882573725" TOTALS="YES" TOTAL_1="90" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="4.134604537063855">
<NAME>Mean degree of protection: PFT comparison</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.177824859960474" CI_END="-8.958807050534878" CI_START="-34.149476761908154" DF="4.0" EFFECT_SIZE="-21.554141906221517" ESTIMABLE="YES" I2="60.69887176251199" ID="CMP-002.04.01" NO="1" P_CHI2="0.037536469823110874" P_Z="7.963890829715585E-4" STUDIES="5" TAU2="112.90943568793172" TOTAL_1="67" TOTAL_2="67" WEIGHT="83.22890340999896" Z="3.3540467433294503">
<NAME>Children</NAME>
<CONT_DATA CI_END="2.7351423125531227" CI_START="-87.63514231255313" EFFECT_SIZE="-42.45" ESTIMABLE="YES" MEAN_1="33.2" MEAN_2="75.65" ORDER="83" SD_1="54.54" SD_2="66.83" SE="23.05406766092018" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.8299355655266565"/>
<CONT_DATA CI_END="-11.327767032630433" CI_START="-53.31223296736958" EFFECT_SIZE="-32.32000000000001" ESTIMABLE="YES" MEAN_1="60.05" MEAN_2="92.37" ORDER="84" SD_1="40.18" SD_2="10.31" SE="10.710519750849317" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="14.620309323729447"/>
<CONT_DATA CI_END="1.8538002002616878" CI_START="-15.253800200261686" EFFECT_SIZE="-6.699999999999999" ESTIMABLE="YES" MEAN_1="25.8" MEAN_2="32.5" ORDER="85" SD_1="14.78" SD_2="5.4" SE="4.364263970018312" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="27.342580147779813"/>
<CONT_DATA CI_END="-8.551667577643677" CI_START="-44.20833242235633" EFFECT_SIZE="-26.380000000000003" ESTIMABLE="YES" MEAN_1="54.71" MEAN_2="81.09" ORDER="86" SD_1="19.72" SD_2="27.74" SE="9.09625511641231" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="17.312492282038505"/>
<CONT_DATA CI_END="-7.061309119729557" CI_START="-38.97869088027045" EFFECT_SIZE="-23.020000000000003" ESTIMABLE="YES" MEAN_1="51.54" MEAN_2="74.56" ORDER="87" SD_1="18.96" SD_2="19.23" SE="8.142338842014732" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="19.123586090924533"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.18023232105092724" CI_END="-7.570326208552263" CI_START="-52.51990357874601" DF="1.0" EFFECT_SIZE="-30.045114893649135" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.671173669238831" P_Z="0.008789080540548761" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.771096590001036" Z="2.6201511359245275">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.5310378375702527" CI_START="-73.31103783757027" EFFECT_SIZE="-36.39000000000001" ESTIMABLE="YES" MEAN_1="35.15" MEAN_2="71.54" ORDER="88" SD_1="55.36" SD_2="28.96" SE="18.83761034835267" STUDY_ID="STD-Boulet-1889" TOTAL_1="11" TOTAL_2="11" WEIGHT="6.743862953556208"/>
<CONT_DATA CI_END="2.0178752997659544" CI_START="-54.63787529976595" EFFECT_SIZE="-26.31" ESTIMABLE="YES" MEAN_1="27.76" MEAN_2="54.07" ORDER="89" SD_1="38.23" SD_2="32.33" SE="14.453263184024104" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.02723363644483"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.478496259141325" CI_END="8.242184924062284" CI_START="0.0029843844260434844" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.15683701197084146" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" I2="80.91329184514217" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.9160423542554061" LOG_CI_START="-2.525145235034478" LOG_EFFECT_SIZE="-0.804551440389536" METHOD="MH" NO="5" P_CHI2="0.005304252581578961" P_Q="0.0" P_Z="0.3594145797915156" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="9.917295390125464" TOTALS="YES" TOTAL_1="152" TOTAL_2="152" WEIGHT="100.00000000000001" Z="0.9164811890994403">
<NAME>ADRS</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.478496259141325" CI_END="8.242184924062284" CI_START="0.0029843844260434844" DF="2.0" EFFECT_SIZE="0.15683701197084146" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" I2="80.91329184514217" ID="CMP-002.05.01" LOG_CI_END="0.9160423542554061" LOG_CI_START="-2.525145235034478" LOG_EFFECT_SIZE="-0.804551440389536" NO="1" P_CHI2="0.005304252581578961" P_Z="0.3594145797915156" STUDIES="10" TAU2="9.917295390125464" TOTAL_1="152" TOTAL_2="152" WEIGHT="100.00000000000001" Z="0.9164811890994403">
<NAME>General side effects</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-Boner-1987" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.4184344489647487" CI_START="0.001144006186792345" EFFECT_SIZE="0.021879021879021878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.3783725679758093" LOG_CI_START="-2.941571626869471" LOG_EFFECT_SIZE="-1.6599720974226404" ORDER="91" O_E="0.0" SE="1.5056358152341085" STUDY_ID="STD-Bundgaard-1980" TOTAL_1="18" TOTAL_2="18" VAR="2.2669392081156787" WEIGHT="33.534639923734034"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.3950933234942853" CI_START="0.0010541639230444108" EFFECT_SIZE="0.02040816326530612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.403300309205138" LOG_CI_START="-2.9770918508518895" LOG_EFFECT_SIZE="-1.6901960800285136" ORDER="95" O_E="0.0" SE="1.5118578920369088" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" VAR="2.2857142857142856" WEIGHT="33.48304482682479"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="96" O_E="0.0" SE="0.0" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="97" O_E="0.0" SE="0.0" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="98" O_E="0.0" SE="0.0" STUDY_ID="STD-Tullett-1982" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="200.59372800808407" CI_START="0.4229134971280437" EFFECT_SIZE="9.210526315789474" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.3023173497508833" LOG_CI_START="-0.3737484542839521" LOG_EFFECT_SIZE="0.9642844477334656" ORDER="99" O_E="0.0" SE="1.5719343000294328" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="2.470977443609023" WEIGHT="32.982315249441186"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.628329441958261" CI_END="9.515249341017519" CI_START="4.595666609820057" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.055457975418788" ESTIMABLE="YES" I2="24.80344359453081" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.2001522975987452" P_Q="0.9221853675044269" P_Z="1.889831218800636E-8" Q="0.009541635904877666" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.194624663879852" TOTALS="YES" TOTAL_1="271" TOTAL_2="272" UNITS="" WEIGHT="100.0" Z="5.621795295183812">
<NAME>High vs low quality</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.487504204712664" CI_END="11.042074611167507" CI_START="3.968329248612118" DF="4.0" EFFECT_SIZE="7.505201929889813" ESTIMABLE="YES" I2="52.87189374493611" ID="CMP-002.06.01" NO="1" P_CHI2="0.07526702668762464" P_Z="3.196154179015237E-5" STUDIES="5" TAU2="8.065437267004839" TOTAL_1="178" TOTAL_2="178" WEIGHT="66.63599343107069" Z="4.159020356359163">
<NAME>Low quality (Jadad 1-2)</NAME>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="100" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.59889015134546"/>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="101" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="19.646209541662785"/>
<CONT_DATA CI_END="16.84085073119181" CI_START="2.4391492688081913" EFFECT_SIZE="9.64" ESTIMABLE="YES" MEAN_1="15.64" MEAN_2="6.0" ORDER="102" SD_1="15.49" SD_2="17.32" SE="3.6739709443597945" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.902388948650012"/>
<CONT_DATA CI_END="7.101147670205071" CI_START="-0.22114767020506987" EFFECT_SIZE="3.4400000000000004" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="1.0" ORDER="103" SD_1="16.2" SD_2="9.3" SE="1.8679668091269717" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="20.498272636644472"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="104" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.990232152767968"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.131283601340718" CI_END="10.177406173803579" CI_START="2.467262534294045" DF="6.0" EFFECT_SIZE="6.322334354048812" ESTIMABLE="YES" I2="2.141209082418089" ID="CMP-002.06.02" NO="2" P_CHI2="0.40864574855831637" P_Z="0.0013074049593794776" STUDIES="7" TAU2="0.6684114878425221" TOTAL_1="93" TOTAL_2="94" WEIGHT="33.36400656892931" Z="3.2143493588516967">
<NAME>High quality (Jadad 3-5)</NAME>
<CONT_DATA CI_END="21.017481953246005" CI_START="0.5625180467539916" EFFECT_SIZE="10.79" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.62" ORDER="105" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.012285406064145"/>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="106" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.7487935486691117"/>
<CONT_DATA CI_END="29.51854447901122" CI_START="1.2814555209887821" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="6.9" ORDER="107" SD_1="17.4" SD_2="10.6" SE="7.203471385380801" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.808384358879114"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="108" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.418654143961991"/>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="109" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.274968925750644"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="110" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="13.086719760829968"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="111" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.0142004247743364"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.09416116507644" CI_END="9.244350534788946" CI_START="4.452448836982338" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.848399685885642" ESTIMABLE="YES" I2="21.953496407742108" I2_Q="90.41133393534865" ID="CMP-002.07" NO="7" P_CHI2="0.2278269488734752" P_Q="0.0012405506413534217" P_Z="2.1163749410102356E-8" Q="10.42897931013056" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.5798010367574147" TOTALS="YES" TOTAL_1="271" TOTAL_2="272" UNITS="" WEIGHT="100.0" Z="5.602208719020759">
<NAME>Effect by severity</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.49792453216401" CI_END="6.385519424609341" CI_START="1.7252914032877529" DF="3.0" EFFECT_SIZE="4.055405413948547" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="0.6827494588433152" P_Z="6.468133285204312E-4" STUDIES="4" TAU2="0.0" TOTAL_1="136" TOTAL_2="137" WEIGHT="58.67786463558461" Z="3.41118439599177">
<NAME>Mild EIB (&lt; 30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="112" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.265847863619849"/>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="113" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="20.18783209335098"/>
<CONT_DATA CI_END="7.101147670205071" CI_START="-0.22114767020506987" EFFECT_SIZE="3.4400000000000004" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="1.0" ORDER="114" SD_1="16.2" SD_2="9.3" SE="1.8679668091269717" STUDY_ID="STD-Spada-1985" TOTAL_1="100" TOTAL_2="100" WEIGHT="21.139535396642334"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="115" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="13.084649281971444"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.16725732278187" CI_END="14.169160142515596" CI_START="7.435083339314128" DF="7.0" EFFECT_SIZE="10.802121740914862" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="0.9500057683983053" P_Z="3.2168519809485873E-10" STUDIES="8" TAU2="0.0" TOTAL_1="135" TOTAL_2="135" WEIGHT="41.322135364415395" Z="6.287950134083681">
<NAME>Severe EIB (=&gt;30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="21.257481953246007" CI_START="0.8025180467539936" EFFECT_SIZE="11.030000000000001" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.38" ORDER="116" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.850386783264196"/>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="117" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.670600544970912"/>
<CONT_DATA CI_END="29.51854447901122" CI_START="1.2814555209887821" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="6.9" ORDER="118" SD_1="17.4" SD_2="10.6" SE="7.203471385380801" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.694033668697472"/>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="119" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.430727366151179"/>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="120" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.12477751266367"/>
<CONT_DATA CI_END="15.231921843603288" CI_START="0.7680781563967116" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="6.0" ORDER="121" SD_1="15.64" SD_2="17.32" SE="3.68982384403375" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.690955449883212"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="122" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="1.9261496237703912"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="123" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.93450441501436"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.756566186450154" CI_END="14.591315711654515" CI_START="7.6454826666619535" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.118399189158234" ESTIMABLE="YES" I2="51.662303047505986" I2_Q="81.4460306308685" ID="CMP-002.08" NO="8" P_CHI2="0.01912525640061591" P_Q="0.001046988496132606" P_Z="3.502101134294283E-10" Q="16.169046850918825" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="17.68918029077856" TOTALS="YES" TOTAL_1="200" TOTAL_2="201" UNITS="" WEIGHT="100.0" Z="6.274743960970866">
<NAME>By delivery method</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.14713028262210578" CI_END="23.48187083328258" CI_START="-1.2318949872990963" DF="1.0" EFFECT_SIZE="11.124987922991743" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="0.7012931301342833" P_Z="0.07763618662589124" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="6.455958260959176" Z="1.7645692538971929">
<NAME>MDI</NAME>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="124" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="3.031777409538212"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="125" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.4241808514209637"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3592952835188092" CI_END="20.148049589202415" CI_START="11.949492638110437" DF="2.0" EFFECT_SIZE="16.048771113656425" ESTIMABLE="YES" I2="15.228923909131565" ID="CMP-002.08.02" NO="2" P_CHI2="0.3073870823987036" P_Z="1.6762048272686745E-14" STUDIES="3" TAU2="2.0398842437911426" TOTAL_1="48" TOTAL_2="48" WEIGHT="32.267336872466664" Z="7.6733048429221045">
<NAME>Spinhaler (Top/Bottom Index)</NAME>
<CONT_DATA CI_END="29.11533338038816" CI_START="12.884666619611838" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="7.0" ORDER="126" SD_1="15.49" SD_2="4.15" SE="4.140552298103882" STUDY_ID="STD-Bundgaard-1983a" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.01357793354087"/>
<CONT_DATA CI_END="19.19328187284132" CI_START="6.806718127158677" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="7.0" ORDER="127" SD_1="12.36" SD_2="4.12" SE="3.159895754051166" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.345370003853288"/>
<CONT_DATA CI_END="21.773260560839148" CI_START="10.226739439160854" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="9.0" ORDER="128" SD_1="11.43" SD_2="2.86" SE="2.945595228472507" STUDY_ID="STD-Bundgaard-1986pdr" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.908388935072503"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7054908704570533" CI_END="12.062307694852691" CI_START="-3.1376750751659213" DF="1.0" EFFECT_SIZE="4.462316309843385" ESTIMABLE="YES" I2="41.365854410465964" ID="CMP-002.08.03" NO="3" P_CHI2="0.19157154380683172" P_Z="0.24981946233035923" STUDIES="2" TAU2="14.28282289377289" TOTAL_1="26" TOTAL_2="27" WEIGHT="18.535328148332518" Z="1.1507880485456634">
<NAME>Nebulisation</NAME>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="129" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.237223369381656"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="130" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="12.29810477895086"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.375602898933362" CI_END="13.549009591388819" CI_START="6.338937069838428" DF="4.0" EFFECT_SIZE="9.943973330613623" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.04" NO="4" P_CHI2="0.6670406903347212" P_Z="6.434775997350256E-8" STUDIES="5" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="42.741376718241646" Z="5.406278378747456">
<NAME>Two or more methods</NAME>
<CONT_DATA CI_END="21.257481953246007" CI_START="0.8025180467539936" EFFECT_SIZE="11.030000000000001" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.38" ORDER="131" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.98979681872566"/>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="132" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.542642285081544"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="133" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.389292493228242"/>
<CONT_DATA CI_END="15.231921843603288" CI_START="0.7680781563967116" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="6.0" ORDER="134" SD_1="15.64" SD_2="17.32" SE="3.68982384403375" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="10.029815527005368"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="135" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.789829594200828"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="44.626147704091025" CI_END="14.230566836480211" CI_START="7.760495455403987" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.995531145942099" ESTIMABLE="YES" I2="66.3874190990837" I2_Q="80.13140045636263" ID="CMP-002.09" NO="9" P_CHI2="8.769646699968714E-5" P_Q="1.2945583506740466E-4" P_Z="2.7067369422232553E-11" Q="25.165336837246674" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="25.37123354922014" TOTALS="YES" TOTAL_1="253" TOTAL_2="254" UNITS="" WEIGHT="100.0" Z="6.661702404077713">
<NAME>By Drug: MSC vs SABA</NAME>
<GROUP_LABEL_1>MSC</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3321695481951843" CI_END="16.492728591155643" CI_START="3.262966473921833" DF="2.0" EFFECT_SIZE="9.877847532538738" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.01" NO="1" P_CHI2="0.513715998703109" P_Z="0.0034250373748779222" STUDIES="3" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="13.499901070797975" Z="2.9267684841187105">
<NAME>Fenoterol</NAME>
<CONT_DATA CI_END="21.257481953246007" CI_START="0.8025180467539936" EFFECT_SIZE="11.030000000000001" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.38" ORDER="136" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.179279452596335"/>
<CONT_DATA CI_END="29.51854447901122" CI_START="1.2814555209887821" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="6.9" ORDER="137" SD_1="17.4" SD_2="10.6" SE="7.203471385380801" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.5261463463090896"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="138" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.79447527189255"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.6483672530673035" CI_END="13.594821399871648" CI_START="2.712639097935952" DF="3.0" EFFECT_SIZE="8.1537302489038" ESTIMABLE="YES" I2="60.77594209670202" ID="CMP-002.09.02" NO="2" P_CHI2="0.05386640148175548" P_Z="0.003312994521614692" STUDIES="4" TAU2="18.34986803270299" TOTAL_1="79" TOTAL_2="80" WEIGHT="28.655639769585356" Z="2.93709794305938">
<NAME>Salbutamol</NAME>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="139" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.52510417814896"/>
<CONT_DATA CI_END="15.231921843603288" CI_START="0.7680781563967116" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="6.0" ORDER="140" SD_1="15.64" SD_2="17.32" SE="3.68982384403375" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.988000357793912"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="141" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="8.202826999222262"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="142" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.93970823442022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.13075400597587605" CI_END="9.583384723882167" CI_START="2.1099784860736146" DF="1.0" EFFECT_SIZE="5.846681604977891" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.03" NO="3" P_CHI2="0.7176516218181781" P_Z="0.002164479900102323" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="12.073410096659881" Z="3.0666833864472873">
<NAME>Terbutaline</NAME>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="143" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="9.331931009001577"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="144" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.741479087658303"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.11056606002311845" CI_END="20.639849459827797" CI_START="1.5745807496468345" DF="1.0" EFFECT_SIZE="11.107215104737316" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.04" NO="4" P_CHI2="0.739500642740051" P_Z="0.0223887701589846" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="7.1444794534817415" Z="2.283706765926594">
<NAME>Reproterol/procaterol</NAME>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="145" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.4490070746175845"/>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="146" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.695472378864157"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2649483807533417" CI_END="22.240941270658993" CI_START="12.953059551155958" DF="2.0" EFFECT_SIZE="17.597000410907476" ESTIMABLE="YES" I2="38.743288813082934" ID="CMP-002.09.05" NO="5" P_CHI2="0.19544557318831335" P_Z="1.1128045751096364E-13" STUDIES="3" TAU2="6.581316401485489" TOTAL_1="50" TOTAL_2="50" WEIGHT="22.62281158070116" Z="7.42677137433671">
<NAME>Fenoterol (Top/Bottom Index)</NAME>
<CONT_DATA CI_END="24.42204980993626" CI_START="14.317950190063742" EFFECT_SIZE="19.37" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="3.13" ORDER="147" SD_1="10.61" SD_2="2.65" SE="2.577623798083119" STUDY_ID="STD-Bundgaard-1980" TOTAL_1="18" TOTAL_2="18" WEIGHT="8.509486173951373"/>
<CONT_DATA CI_END="29.11533338038816" CI_START="12.884666619611838" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="7.0" ORDER="148" SD_1="15.49" SD_2="4.15" SE="4.140552298103882" STUDY_ID="STD-Bundgaard-1983a" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.407898603522748"/>
<CONT_DATA CI_END="19.19328187284132" CI_START="6.806718127158677" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="7.0" ORDER="149" SD_1="12.36" SD_2="4.12" SE="3.159895754051166" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" WEIGHT="7.705426803227041"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.974005618829526" CI_END="21.279669241379555" CI_START="-0.279934582288643" DF="1.0" EFFECT_SIZE="10.499867329545456" ESTIMABLE="YES" I2="85.6610382231405" ID="CMP-002.09.06" NO="6" P_CHI2="0.008270294552050084" P_Z="0.05625347650348391" STUDIES="2" TAU2="51.824928125" TOTAL_1="32" TOTAL_2="32" WEIGHT="16.00375802877388" Z="1.9090667877454934">
<NAME>Salbutamol (Top/Bottom Index)</NAME>
<CONT_DATA CI_END="10.772289428416409" CI_START="-0.7722894284164088" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="9.0" ORDER="150" SD_1="8.33" SD_2="8.33" SE="2.9450997436419706" STUDY_ID="STD-Bundgaard-1986neb" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.002222010258038"/>
<CONT_DATA CI_END="21.773260560839148" CI_START="10.226739439160854" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="9.0" ORDER="151" SD_1="11.43" SD_2="2.86" SE="2.945595228472507" STUDY_ID="STD-Bundgaard-1986pdr" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.001536018515845"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="44.2455845721092" CI_END="14.315973382396932" CI_START="7.874687557214811" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.095330469805871" ESTIMABLE="YES" I2="66.09831208003645" I2_Q="93.76377232155814" ID="CMP-002.10" NO="10" P_CHI2="1.006394863570792E-4" P_Q="6.217240913208855E-5" P_Z="1.456127647490352E-11" Q="16.035335006400075" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="25.03187663854417" TOTALS="SUB" TOTAL_1="253" TOTAL_2="254" UNITS="" WEIGHT="200.00000000000003" Z="6.752207154780164">
<NAME>By method used to calculate change</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.289369804807643" CI_END="10.29628411406373" CI_START="5.231285685187759" DF="10.0" EFFECT_SIZE="7.763784899625744" ESTIMABLE="YES" I2="11.421096368537398" ID="CMP-002.10.01" NO="1" P_CHI2="0.33542248689364096" P_Z="1.8714858161489404E-9" STUDIES="11" TAU2="2.0869673543238028" TOTAL_1="171" TOTAL_2="172" WEIGHT="100.0" Z="6.008585787600844">
<NAME>Percent Change Index</NAME>
<CONT_DATA CI_END="21.017481953246005" CI_START="0.5625180467539916" EFFECT_SIZE="10.79" ESTIMABLE="YES" MEAN_1="13.41" MEAN_2="2.62" ORDER="152" SD_1="15.64" SD_2="17.32" SE="5.218198923000157" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.422770948880672"/>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="153" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="3.9690961358599726"/>
<CONT_DATA CI_END="29.51854447901122" CI_START="1.2814555209887821" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="6.9" ORDER="154" SD_1="17.4" SD_2="10.6" SE="7.203471385380801" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.722513105669164"/>
<CONT_DATA CI_END="25.189259415165843" CI_START="6.010740584834153" EFFECT_SIZE="15.599999999999998" ESTIMABLE="YES" MEAN_1="19.33" MEAN_2="3.73" ORDER="155" SD_1="18.28" SD_2="4.99" SE="4.892569195559051" STUDY_ID="STD-Godfrey-1976" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.989063665431752"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="156" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.793225764446466"/>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="157" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="7.631353790874867"/>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="158" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="15.255419327789141"/>
<CONT_DATA CI_END="16.84085073119181" CI_START="2.4391492688081913" EFFECT_SIZE="9.64" ESTIMABLE="YES" MEAN_1="15.64" MEAN_2="6.0" ORDER="159" SD_1="15.49" SD_2="17.32" SE="3.6739709443597945" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="11.424530041273455"/>
<CONT_DATA CI_END="7.288258112735475" CI_START="-3.688258112735475" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.4" ORDER="160" SD_1="6.8" SD_2="7.2" SE="2.800183144193544" STUDY_ID="STD-Vazquez-1984" TOTAL_1="12" TOTAL_2="13" WEIGHT="13.390556253084695"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="161" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.4447286209710555"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="162" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="12.95674234571877"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.920879760901485" CI_END="20.287123689384053" CI_START="9.137781296452168" DF="4.0" EFFECT_SIZE="14.71245249291811" ESTIMABLE="YES" I2="76.36056720146037" ID="CMP-002.10.02" NO="2" P_CHI2="0.0020025831063970045" P_Z="2.3078510726703815E-7" STUDIES="5" TAU2="30.51732982830482" TOTAL_1="82" TOTAL_2="82" WEIGHT="100.00000000000003" Z="5.172659694917346">
<NAME>Top-Bottom Index</NAME>
<CONT_DATA CI_END="24.42204980993626" CI_START="14.317950190063742" EFFECT_SIZE="19.37" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="3.13" ORDER="163" SD_1="10.61" SD_2="2.65" SE="2.577623798083119" STUDY_ID="STD-Bundgaard-1980" TOTAL_1="18" TOTAL_2="18" WEIGHT="22.050072904596146"/>
<CONT_DATA CI_END="29.11533338038816" CI_START="12.884666619611838" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="7.0" ORDER="164" SD_1="15.49" SD_2="4.15" SE="4.140552298103882" STUDY_ID="STD-Bundgaard-1983a" TOTAL_1="15" TOTAL_2="15" WEIGHT="16.560549759238892"/>
<CONT_DATA CI_END="19.19328187284132" CI_START="6.806718127158677" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="7.0" ORDER="165" SD_1="12.36" SD_2="4.12" SE="3.159895754051166" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" WEIGHT="19.946374850427826"/>
<CONT_DATA CI_END="10.772289428416409" CI_START="-0.7722894284164088" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="9.0" ORDER="166" SD_1="8.33" SD_2="8.33" SE="2.9450997436419706" STUDY_ID="STD-Bundgaard-1986neb" TOTAL_1="16" TOTAL_2="16" WEIGHT="20.7223984003453"/>
<CONT_DATA CI_END="21.773260560839148" CI_START="10.226739439160854" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="9.0" ORDER="167" SD_1="11.43" SD_2="2.86" SE="2.945595228472507" STUDY_ID="STD-Bundgaard-1986pdr" TOTAL_1="16" TOTAL_2="16" WEIGHT="20.720604085391855"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.616514179452523" CI_END="22.286880511758255" CI_START="8.071847953309547" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="15.179364232533901" ESTIMABLE="YES" I2="81.9456718322444" I2_Q="0.0" ID="CMP-002.11" NO="11" P_CHI2="8.473942390704314E-4" P_Q="1.0" P_Z="2.840991331289203E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="42.60489496113778" TOTALS="SUB" TOTAL_1="65" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="4.185851433213835">
<NAME>Effect by severity (TBI)</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="16.616514179452523" CI_END="22.286880511758255" CI_START="8.071847953309547" DF="3.0" EFFECT_SIZE="15.179364232533901" ESTIMABLE="YES" I2="81.9456718322444" ID="CMP-002.11.03" NO="3" P_CHI2="8.473942390704314E-4" P_Z="2.840991331289203E-5" STUDIES="4" TAU2="42.60489496113778" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="4.185851433213835">
<NAME>Top/Bottom index (Severe EIB)</NAME>
<CONT_DATA CI_END="24.42204980993626" CI_START="14.317950190063742" EFFECT_SIZE="19.37" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="3.13" ORDER="168" SD_1="10.61" SD_2="2.65" SE="2.577623798083119" STUDY_ID="STD-Bundgaard-1980" TOTAL_1="18" TOTAL_2="18" WEIGHT="26.701876324859395"/>
<CONT_DATA CI_END="29.11533338038816" CI_START="12.884666619611838" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="7.0" ORDER="169" SD_1="15.49" SD_2="4.15" SE="4.140552298103882" STUDY_ID="STD-Bundgaard-1983a" TOTAL_1="15" TOTAL_2="15" WEIGHT="22.009410303184104"/>
<CONT_DATA CI_END="10.772289428416409" CI_START="-0.7722894284164088" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="9.0" ORDER="170" SD_1="8.33" SD_2="8.33" SE="2.9450997436419706" STUDY_ID="STD-Bundgaard-1986neb" TOTAL_1="16" TOTAL_2="16" WEIGHT="25.645086497936944"/>
<CONT_DATA CI_END="21.773260560839148" CI_START="10.226739439160854" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="9.0" ORDER="171" SD_1="11.43" SD_2="2.86" SE="2.945595228472507" STUDY_ID="STD-Bundgaard-1986pdr" TOTAL_1="16" TOTAL_2="16" WEIGHT="25.64362687401955"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.481890243992674" CI_END="10.090234305780575" CI_START="4.731557594778497" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.410895950279536" ESTIMABLE="YES" I2="0.0" I2_Q="32.04221548693928" ID="CMP-002.12" NO="12" P_CHI2="0.8704889913857644" P_Q="0.22510921856995159" P_Z="5.921758232920925E-8" Q="1.4715017671122155" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="5.421147771762265">
<NAME>Effect by steroid use</NAME>
<GROUP_LABEL_1>MCS</GROUP_LABEL_1>
<GROUP_LABEL_2>SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9919511881258593" CI_END="9.530378258167183" CI_START="3.1641261825195457" DF="3.0" EFFECT_SIZE="6.347252220343364" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" NO="1" P_CHI2="0.8031995370708002" P_Z="9.297512774015416E-5" STUDIES="4" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="70.85123946021992" Z="3.9082290819907035">
<NAME>No recent steroid use</NAME>
<CONT_DATA CI_END="31.8923816034999" CI_START="-4.432381603499893" EFFECT_SIZE="13.730000000000002" ESTIMABLE="YES" MEAN_1="27.26" MEAN_2="13.53" ORDER="172" SD_1="20.34" SD_2="28.08" SE="9.26669150390642" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.176253736924819"/>
<CONT_DATA CI_END="16.191770628780123" CI_START="-5.791770628780122" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.5" ORDER="173" SD_1="7.57" SD_2="18.75" SE="5.608149290232783" STUDY_ID="STD-Neijens-1981a" TOTAL_1="13" TOTAL_2="13" WEIGHT="5.9418243342987385"/>
<CONT_DATA CI_END="9.521995025599692" CI_START="1.8580049744003069" EFFECT_SIZE="5.6899999999999995" ESTIMABLE="YES" MEAN_1="12.93" MEAN_2="7.24" ORDER="174" SD_1="3.59" SD_2="5.4" SE="1.9551354289292968" STUDY_ID="STD-Pichaipat-1995" TOTAL_1="11" TOTAL_2="11" WEIGHT="48.888335272875246"/>
<CONT_DATA CI_END="15.20085073119181" CI_START="0.7991492688081907" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="6.0" ORDER="175" SD_1="15.49" SD_2="17.32" SE="3.6739709443597945" STUDY_ID="STD-Rohr-1987" TOTAL_1="40" TOTAL_2="40" WEIGHT="13.844826116121116"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.018437288754599213" CI_END="14.958965144945521" CI_START="5.033576743917356" DF="2.0" EFFECT_SIZE="9.996270944431439" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.02" NO="2" P_CHI2="0.990823717351898" P_Z="7.88323845287934E-5" STUDIES="3" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="29.14876053978008" Z="3.947922285592422">
<NAME>Some on ICS</NAME>
<CONT_DATA CI_END="21.30917119149168" CI_START="-1.089171191491678" EFFECT_SIZE="10.11" ESTIMABLE="YES" MEAN_1="18.95" MEAN_2="8.84" ORDER="176" SD_1="13.74" SD_2="16.38" SE="5.713967848301964" STUDY_ID="STD-Obata-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.723785572791672"/>
<CONT_DATA CI_END="25.74067395419845" CI_START="-7.980673954198451" EFFECT_SIZE="8.879999999999999" ESTIMABLE="YES" MEAN_1="24.38" MEAN_2="15.5" ORDER="177" SD_1="24.25" SD_2="17.32" SE="8.602542744251066" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.5252551291093734"/>
<CONT_DATA CI_END="15.960805771254776" CI_START="4.239194228745222" EFFECT_SIZE="10.1" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="2.5" ORDER="178" SD_1="8.9" SD_2="5.3" SE="2.9902619729158624" STUDY_ID="STD-Zanconato-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.899719837879037"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>SABA vs combination SABA + MCS</NAME>
<CONT_OUTCOME CHI2="0.8294237522094486" CI_END="4.619657164837767" CI_START="-1.100587898723878" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7595346330569446" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.9344604540039139" P_Q="0.9007444963276493" P_Z="0.22790963787204233" Q="0.015555308570004645" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="65" UNITS="" WEIGHT="200.0" Z="1.2057611070932912">
<NAME>Maximum percent decrease in PFT</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+B2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS+SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6087855525651393" CI_END="4.92060157498767" CI_START="-1.2536560941737394" DF="1.0" EFFECT_SIZE="1.8334727404069655" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.4352456180544009" P_Z="0.24440794166011082" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.1640397049777433">
<NAME>Children</NAME>
<CONT_DATA CI_END="4.765149568914368" CI_START="-1.4851495689143688" EFFECT_SIZE="1.6399999999999997" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="2.45" ORDER="179" SD_1="4.48" SD_2="2.81" SE="1.5944933649623918" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" WEIGHT="97.58159074491293"/>
<CONT_DATA CI_END="29.491341297050923" CI_START="-10.211341297050927" EFFECT_SIZE="9.639999999999999" ESTIMABLE="YES" MEAN_1="13.53" MEAN_2="3.89" ORDER="180" SD_1="28.08" SD_2="25.45" SE="10.128421467759496" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.4184092550870706"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.20508289107430464" CI_END="8.910631332453434" CI_START="-6.287573173857328" DF="2.0" EFFECT_SIZE="1.311529079298053" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.9025408294380797" P_Z="0.7351595868023411" STUDIES="3" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.338270189617963">
<NAME>Adults</NAME>
<CONT_DATA CI_END="11.135326553826715" CI_START="-12.555326553826717" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="2.62" MEAN_2="3.33" ORDER="181" SD_1="20.4" SD_2="17.73" SE="6.043645009429326" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="41.155748152335256"/>
<CONT_DATA CI_END="23.671294723864246" CI_START="-16.071294723864245" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="16.4" ORDER="182" SD_1="21.3" SD_2="19.2" SE="10.138601974631413" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="14.624204362935593"/>
<CONT_DATA CI_END="13.797538315003395" CI_START="-9.057538315003397" EFFECT_SIZE="2.369999999999999" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="13.13" ORDER="183" SD_1="17.32" SD_2="10.39" SE="5.830483827836817" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="44.22004748472915"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5569059371156908" CI_END="1.3942258796270597" CI_START="0.1519960407414679" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4603442338105296" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.14433313985143678" LOG_CI_START="-0.8181677245981726" LOG_EFFECT_SIZE="-0.33691729237336787" METHOD="MH" NO="2" P_CHI2="0.45911587259127273" P_Q="0.0" P_Z="0.17001805447122315" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.3721457989508625">
<NAME>Complete protection: post exercise fall PFT &lt;15% (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors MCS+SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors SABA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3938120592807393" CI_END="5.028214614288228" CI_START="0.0934020179133946" DF="1.0" EFFECT_SIZE="0.6853067863928837" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" I2="28.254315684710136" ID="CMP-003.02.01" LOG_CI_END="0.7014138059693659" LOG_CI_START="-1.0296437409092496" LOG_EFFECT_SIZE="-0.1641149674699419" NO="1" P_CHI2="0.23776259674097033" P_Z="0.7101657973165854" STUDIES="3" TAU2="0.7225969349966779" TOTAL_1="32" TOTAL_2="32" WEIGHT="55.47135965467585" Z="0.3716334285305004">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="184" O_E="0.0" SE="0.0" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9093297707241907" CI_START="0.06925540416652255" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.280880944232929" LOG_CI_START="-1.1595463318934542" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="185" O_E="0.0" SE="0.8461141122266492" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.7159090909090908" WEIGHT="44.649806713610744"/>
<DICH_DATA CI_END="100.5098367576078" CI_START="0.11921468492289741" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="2.002208567632053" LOG_CI_START="-0.9236702446950389" LOG_EFFECT_SIZE="0.5392691614685069" ORDER="186" O_E="0.0" SE="1.718675697694639" STUDY_ID="STD-Svenonius-1988" TOTAL_1="7" TOTAL_2="7" VAR="2.9538461538461536" WEIGHT="10.821552941065104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.879467514294643" CI_START="0.06786550947970635" DF="0.0" EFFECT_SIZE="0.3571428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.2740348235403847" LOG_CI_START="-1.1683508862248233" LOG_EFFECT_SIZE="-0.44715803134221926" NO="2" P_CHI2="1.0" P_Z="0.22427922672409095" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="44.52864034532414" Z="1.2152278421716276">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.879467514294643" CI_START="0.06786550947970635" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2740348235403847" LOG_CI_START="-1.1683508862248233" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="187" O_E="0.0" SE="0.8472645058404977" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.7178571428571427" WEIGHT="44.52864034532414"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1310759289137187" CI_END="1.2056043686944122" CI_START="0.11287393432495156" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3688920009079727" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.08120481304283847" LOG_CI_START="-0.9474063369573111" LOG_EFFECT_SIZE="-0.43310076195723635" METHOD="MH" NO="3" P_CHI2="0.9365634995012369" P_Q="0.0" P_Z="0.09884049732542151" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.6505010569113798">
<NAME>Clinical Protection: 50% improvement over placebo (entered as proportion achieved)</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors MCS+SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors SABA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.536437027512144E-5" CI_END="1.5167199156861435" CI_START="0.05974800810653717" DF="1.0" EFFECT_SIZE="0.3010332104897433" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.18090538942055182" LOG_CI_START="-1.2236765687523639" LOG_EFFECT_SIZE="-0.521385589665906" NO="1" P_CHI2="0.9940632161621535" P_Z="0.14564419074244314" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="53.630060165174754" Z="1.4550905653560315">
<NAME>Children</NAME>
<DICH_DATA CI_END="8.319106708415976" CI_START="0.011134320365208224" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.9200766949885941" LOG_CI_START="-1.9533362869952662" LOG_EFFECT_SIZE="-0.516629796003336" ORDER="188" O_E="0.0" SE="1.687857009240976" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" VAR="2.8488612836438922" WEIGHT="12.81463841171721"/>
<DICH_DATA CI_END="1.9148983992764752" CI_START="0.046999882622496075" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.28214573610926486" LOG_CI_START="-1.3279032266699402" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="189" O_E="0.0" SE="0.9457507306074071" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.8944444444444444" WEIGHT="40.81542175345754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.65630569178903" CI_START="0.0819852091763971" DF="0.0" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.4242780528562651" LOG_CI_START="-1.0862644909391137" LOG_EFFECT_SIZE="-0.3309932190414244" NO="2" P_CHI2="1.0" P_Z="0.39037210724100646" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="46.369939834825246" Z="0.8589427568430645">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.65630569178903" CI_START="0.0819852091763971" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.4242780528562651" LOG_CI_START="-1.0862644909391137" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="190" O_E="0.0" SE="0.8873001675315898" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.7873015873015873" WEIGHT="46.369939834825246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.13403936224537963" CI_END="6.471825714729853" CI_START="-26.987008737044384" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.257591511157266" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.7142802062974638" P_Q="1.0" P_Z="0.22946198190334766" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.2017459818553804">
<NAME>Mean degree of protection: PFT comparison</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS+SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.13403936224537963" CI_END="6.471825714729853" CI_START="-26.987008737044384" DF="1.0" EFFECT_SIZE="-10.257591511157266" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="0.7142802062974638" P_Z="0.22946198190334766" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.2017459818553804">
<NAME>Children</NAME>
<CONT_DATA CI_END="8.516116668039619" CI_START="-26.876116668039632" EFFECT_SIZE="-9.180000000000007" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="88.18" ORDER="191" SD_1="25.45" SD_2="15.78" SE="9.028796859342485" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" WEIGHT="89.3728647814866"/>
<CONT_DATA CI_END="31.998352930529528" CI_START="-70.63835293052952" EFFECT_SIZE="-19.319999999999993" ESTIMABLE="YES" MEAN_1="75.65" MEAN_2="94.97" ORDER="192" SD_1="66.83" SD_2="74.15" SE="26.18331425236491" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="15" WEIGHT="10.627135218513406"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="54.07" MEAN_2="61.1" ORDER="193" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.099071384231337" CI_START="0.14086349409321747" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.851201543214856" LOG_CI_START="-0.8512015432148559" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="82" WEIGHT="100.0" Z="0.0">
<NAME>ADRS</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS+SABA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.099071384231337" CI_START="0.14086349409321747" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.851201543214856" LOG_CI_START="-0.8512015432148559" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="6" TAU2="0.0" TOTAL_1="82" TOTAL_2="82" WEIGHT="100.0" Z="0.0">
<NAME>General side effects</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="194" O_E="0.0" SE="0.0" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="195" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="197" O_E="0.0" SE="0.0" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.099071384231337" CI_START="0.14086349409321747" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.851201543214856" LOG_CI_START="-0.8512015432148559" LOG_EFFECT_SIZE="0.0" ORDER="198" O_E="0.0" SE="1.0" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" VAR="1.0" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="199" O_E="0.0" SE="0.0" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8294237522094484" CI_END="4.619657164837767" CI_START="-1.100587898723878" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7595346330569446" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.9344604540039139" P_Q="0.5839012608579168" P_Z="0.22790963787204233" Q="0.2999700921590782" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" UNITS="" WEIGHT="100.00000000000001" Z="1.2057611070932912">
<NAME>Effect by severity</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MSC+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SABA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MCS+SABA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.14135590134971815" CI_END="4.508822732805704" CI_START="-1.534681906120744" DF="1.0" EFFECT_SIZE="1.4870704133424797" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="0.7069368860793721" P_Z="0.33477470088001926" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="89.58835255123209" Z="0.9645411484764227">
<NAME>Mild EIB (&lt; 30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="11.135326553826715" CI_START="-12.555326553826717" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="2.62" MEAN_2="3.33" ORDER="200" SD_1="20.4" SD_2="17.73" SE="6.043645009429326" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.830089244675792"/>
<CONT_DATA CI_END="4.765149568914368" CI_START="-1.4851495689143688" EFFECT_SIZE="1.6399999999999997" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="2.45" ORDER="201" SD_1="4.48" SD_2="2.81" SE="1.5944933649623918" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" WEIGHT="83.7582633065563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.38809775870065205" CI_END="12.96788918815105" CI_START="-4.759913446191321" DF="2.0" EFFECT_SIZE="4.103987870979864" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="0.8236177081987885" P_Z="0.36416166319413823" STUDIES="3" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.411647448767921" Z="0.9074636700351708">
<NAME>Severe EIB (=&gt;30% maximum fall on placebo)</NAME>
<CONT_DATA CI_END="29.491341297050923" CI_START="-10.211341297050927" EFFECT_SIZE="9.639999999999999" ESTIMABLE="YES" MEAN_1="13.53" MEAN_2="3.89" ORDER="202" SD_1="28.08" SD_2="25.45" SE="10.128421467759496" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.075819400199267"/>
<CONT_DATA CI_END="23.671294723864246" CI_START="-16.071294723864245" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="16.4" ORDER="203" SD_1="21.3" SD_2="19.2" SE="10.138601974631413" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.071652694848502"/>
<CONT_DATA CI_END="13.797538315003395" CI_START="-9.057538315003397" EFFECT_SIZE="2.369999999999999" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="13.13" ORDER="204" SD_1="17.32" SD_2="10.39" SE="5.830483827836817" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.2641753537201526"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9480987344072873" CI_END="1.6421154778832465" CI_START="-0.8110114360794374" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4155520209019045" ESTIMABLE="YES" I2="0.0" I2_Q="3.789464633918993" ID="CMP-003.07" NO="7" P_CHI2="0.9375722538594229" P_Q="0.30796436628139423" P_Z="0.5066752564644689" Q="1.0393872107612756" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="129" UNITS="" WEIGHT="100.00000000000001" Z="0.6640235285298884">
<NAME>By method used to calculate change</NAME>
<GROUP_LABEL_1>SABA</GROUP_LABEL_1>
<GROUP_LABEL_2>MCS+SABA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SABA alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8294237522094485" CI_END="4.619657164837768" CI_START="-1.1005878987238777" DF="4.0" EFFECT_SIZE="1.7595346330569448" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.9344604540039139" P_Z="0.22790963787204221" STUDIES="5" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="18.39122952788298" Z="1.2057611070932914">
<NAME>Percent Change Index</NAME>
<CONT_DATA CI_END="11.135326553826715" CI_START="-12.555326553826717" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="2.62" MEAN_2="3.33" ORDER="205" SD_1="20.4" SD_2="17.73" SE="6.043645009429326" STUDY_ID="STD-Clarke-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.0722250946687437"/>
<CONT_DATA CI_END="4.765149568914368" CI_START="-1.4851495689143688" EFFECT_SIZE="1.6399999999999997" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="2.45" ORDER="206" SD_1="4.48" SD_2="2.81" SE="1.5944933649623918" STUDY_ID="STD-de-Benedictis-1998" TOTAL_1="11" TOTAL_2="11" WEIGHT="15.404174453277355"/>
<CONT_DATA CI_END="29.491341297050923" CI_START="-10.211341297050927" EFFECT_SIZE="9.639999999999999" ESTIMABLE="YES" MEAN_1="13.53" MEAN_2="3.89" ORDER="207" SD_1="28.08" SD_2="25.45" SE="10.128421467759496" STUDY_ID="STD-Debelic-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.3817687104749709"/>
<CONT_DATA CI_END="23.671294723864246" CI_START="-16.071294723864245" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="16.4" ORDER="208" SD_1="21.3" SD_2="19.2" SE="10.138601974631413" STUDY_ID="STD-Gehrke-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.3810024021301611"/>
<CONT_DATA CI_END="13.797538315003395" CI_START="-9.057538315003397" EFFECT_SIZE="2.369999999999999" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="13.13" ORDER="209" SD_1="17.32" SD_2="10.39" SE="5.830483827836817" STUDY_ID="STD-Woolley-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="1.1520588673317484"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0792877714365632" CI_END="1.4704297295906534" CI_START="-1.2450814799310774" DF="3.0" EFFECT_SIZE="0.11267412482978793" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="0.7820763307620169" P_Z="0.8707950157911284" STUDIES="4" TAU2="0.0" TOTAL_1="64" TOTAL_2="64" WEIGHT="81.60877047211703" Z="0.1626487313929001">
<NAME>Top/Bottom index</NAME>
<CONT_DATA CI_END="1.9700622785704818" CI_START="-3.9700622785704818" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="8.0" ORDER="210" SD_1="4.15" SD_2="4.15" SE="1.51536574243096" STUDY_ID="STD-Bundgaard-1983a" TOTAL_1="15" TOTAL_2="15" WEIGHT="17.054890332978044"/>
<CONT_DATA CI_END="3.769719854298081" CI_START="-1.769719854298081" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="6.0" ORDER="211" SD_1="4.12" SD_2="4.12" SE="1.4131483415742727" STUDY_ID="STD-Bundgaard-1983p" TOTAL_1="17" TOTAL_2="17" WEIGHT="19.61138902863585"/>
<CONT_DATA CI_END="5.760456073743196" CI_START="-3.760456073743196" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="8.0" ORDER="212" SD_1="8.33" SD_2="5.0" SE="2.4288487499224813" STUDY_ID="STD-Bundgaard-1986neb" TOTAL_1="16" TOTAL_2="16" WEIGHT="6.638698095723021"/>
<CONT_DATA CI_END="1.9818424688200393" CI_START="-1.9818424688200393" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="9.0" ORDER="213" SD_1="2.86" SD_2="2.86" SE="1.0111626970967629" STUDY_ID="STD-Bundgaard-1986pdr" TOTAL_1="16" TOTAL_2="16" WEIGHT="38.30379301478011"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>